Flow cytometry method for assessing non-associated virus size particles of influenza virus type in biological materials

The flow cytometry method directly detects non-associated virus-sized particles using fluorescent antibody stains, addressing inaccuracies in traditional methods by controlling residual stain concentrations and eliminating the need for separation, thereby enhancing quantification accuracy and efficiency.

CN119064246APending Publication Date: 2024-12-03SARTORIUS BIOANALYTICAL INSTRUMENTS INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411133826.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2016-01-18
Filing Date
2016-03-23
Publication Date
2024-12-03

AI Technical Summary

Technical Problem

Current methods for quantifying viral particles, particularly non-enveloped viruses like adenovirus and adeno-associated virus, are inaccurate due to high background fluorescent signals from serum proteins and other interfering substances, and traditional flow cytometry struggles with distinguishing influenza virus particles from egg-derived contaminants.

Method used

A flow cytometry method that uses fluorescent antibody stains without separating stained viral particles from residual unbound stain, allowing direct detection of non-associated virus-sized particles by fluorescence emission without light scattering, suitable for quantifying influenza virus types and other viruses.

Benefits of technology

Enables rapid, accurate, and cost-effective quantification of non-associated virus-sized particles, including influenza virus types, by controlling residual unbound fluorescent stain concentrations and using specific antibody stains, reducing the need for time-consuming separation processes.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0004998767230000121
    Figure BDA0004998767230000121
  • Figure BDA0004998767230000131
    Figure BDA0004998767230000131
  • Figure BDA0004998767230000141
    Figure BDA0004998767230000141
Patent Text Reader

Abstract

The present application relates to methods and fluid samples for assessing non-associated virus size particles with specific epitopes in a biological material using a fluorescent antibody stain that specifically binds to an epitope wherein the fluid sample with virus size particles and fluorescent antibody stain is subjected to flow cytometry, in some embodiments, the method includes identifying a fluorescent emission detection event indicative of the passage of a non-associated labeled virus size particle through a flow cell of a flow cytometer, the non-associated labeled virus size particle comprising the virus size particle and a fluorescent antibody stain.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] This application is a divisional application of a Chinese invention application (invention name: Flow cytometric method for evaluating non-associated virus-sized particles of influenza virus types in biological materials, application date: March 23, 2016; application number: 202010535312.8).

[0002] Cross-references

[0003] This application claims priority to and is incorporated by reference into and is filed on U.S. Provisional Patent Applications No. 62 / 280,079, entitled FLOW CYTOMETRY METHOD FOR EVALUATING BIOLOGICAL MATERIAL FOR UNASSOCIATED PARTICLES OF VIRUS SIZE, filed January 18, 2016, and having Agent Docket No. 50911-00035; No. 62 / 280,029, entitled EVALUATING BIOLOGICAL MATERIAL FOR UNASSOCIATED VIRUS-SIZE PARTICLES OF BACULOVIRUS VIRAL TYPE, filed January 18, 2016, and having Agent Docket No. 50911-00036; No. 62 / 280,042, entitled EVALUATING BIOLOGICAL MATERIAL FOR UNASSOCIATED VIRUS-SIZE PARTICLES OF BACULOVIRUS VIRAL TYPE, filed January 18, 2016, and having Agent Docket No. 50911-00037; ADENOVIRUS VIRAL TYPE, filed January 18, 2016, and its agency docket number is 50911-00037; Serial No. 62 / 280,048, entitled EVALUATING BIOLOGICAL MATERIAL FOR UNASSOCIATED VIRUS-SIZE PARTICLES OF ADENO-ASSOCIATED VIRUS VIRAL TYPE, filed January 18, 2016, and its agency docket number is 50911-00041; Serial No. 62 / 273,874, entitled FLOW CYTOMETRY METHOD FOR EVALUATING BIOLOGICAL MATERIAL FOR UNASSOCIATED PARTICLES OF VIRUS SIZE, filed December 31, 2015, and having Agency Docket No. 50911-00040; and Serial No. 62 / 137,102, entitled FLOW CYTOMETRYMETHOD FOR EVALUATING BIOLOGICAL MATERIAL FOR UNASSOCIATED PARTICLES OF VIRUSSIZE, filed March 23, 2015, and having Agency Docket No. 50911-00027. Technical Field

[0004] The present invention relates to flow cytometric assessment of non-associated virus-sized particles in biological material, including assessing the presence of such virus-sized non-associated particles having epitopes indicative of influenza virus type. Background Art

[0005] There are many situations where it is desirable to quantify free, non-associated virus particles (formally called virions) quickly, reliably, accurately and cost-effectively. Quantification or quantification refers to counting and determining the concentration of individual virus particles.

[0006] Some important situations relate to the field of influenza virus. Influenza virus is a virus in the orthomyxovirus family, including three categories: influenza A, B and C viruses (also known as influenza A virus, influenza B virus and influenza C virus). Infectious influenza is mainly caused by influenza A and B viruses in humans. The serotypes of influenza A and B viruses are prone to continuous evolution due to genetic drift, which requires the continuous development of new vaccines. The demand for this influenza A virus is getting higher and higher, and the serotype of the virus is also prone to occasional rapid transformation through genetic drift, which may cause a pandemic situation, and there is an urgent need to study and accelerate vaccine development. Relative to traditional vaccines, for example, in the field of virus-like particles with enhanced vaccine immunogenicity, important research also involves the development of viral agents used as more general influenza vaccines. In vaccine production operations and research and monitoring purposes, it is an important challenge to quickly and accurately evaluate influenza viruses and related viral agents, partly due to this genetic drift and genetic drift.

[0007] Furthermore, following significant setbacks over the past decade, the field of gene therapy is currently experiencing a resurgence, both in terms of the breadth and depth of different applications being pursued using this approach. However, with this continued success comes the recognition of the challenges inherent in moving from early research and development to late-stage clinical trials and product launches. The primary issue is the continuous and compliant production of viral vectors at levels necessary to support commercialization. As the number of successful trials grows and the likelihood of multiple product certifications increases, it is recognized that current manufacturing technologies are failing to keep pace, and this is seen as an area in urgent need of innovation. One of the most problematic steps is quantification of viral vectors during growth, harvesting, purification, and release. Current methods such as quantitative PCR and absorbance readings at 260nm and 280nm are highly variable, resulting in an over- or under-assessment of particles at any given step. The consequences of manufacturing are product losses, delays, and cost overruns, which are serious, but still not as great as the risks associated with administering too little (no therapeutic effect) or too much (adverse immune response) product to patients. Clearly, there is a critical need for rapid, more accurate methods for quantifying viral particles for vector-mediated gene therapy.

[0008] Some traditional methods for virus quantification include viral plaque testing (plaque titer assays), transmission electron microscopy (TEM), and single immunodiffusion (SRID) assays. These traditional methods often have one or more of the following limitations: time consuming, expensive, highly technical, high variability in results, and subjectivity. Some newer methods that are recommended and commonly used for virus quantification include field flow fractionation and multi-angle light scattering (FFF-MALS), tunable resistive pulse sensing (TRPS), and nanoparticle tracking analysis (NTS). All of these newer methods may have some advantages over traditional quantification methods in some cases, but also have limitations, including generally providing limited viral data.

[0009] Carefully controlled flow cytometry using a combination of fluorescent stains for proteins and nucleic acids has also been used to quantify various viruses. Flow cytometry is an analytical technique in which the physical and / or chemical properties of particles are measured as they flow through a fluid sample through a research tube commonly called a flow cell. Although fluid samples can be studied by subjecting them to a variety of stimuli, light is a common stimulation technique. An apparatus containing a flow cell and associated fluid flow, light delivery, and light detection components is commonly referred to as a flow cytometer.

[0010] Virus has been used Flow cytometry (ViroCyt, Inc.) is used to detect the presence of free, non-associated viral particles (sometimes called virions) of a variety of viruses by using a very low and precisely controlled flow rate of the sample through the flow cell and combining two fluorescent dyes with different fluorescence emission characteristics, one of which has an affinity for labeled nucleic acids and the other for labeled proteins. The dyes are non-specific for the virus type, but the identification of simultaneous detection events of two different fluorescence emissions from the two fluorescent dyes can indicate that such non-associated viral particles have passed through the flow cell. Unlike techniques such as field-flow fractionation and multi-angle light scattering (FFF-MALS), tunable resistive pulse sensing (TRPS), and nanoparticle tracking analysis (NTS), which only measure the presence of particles, virions or other particles, Virus cytometry can detect the presence of free, non-associated viral particles (sometimes called virions) of a variety of viruses by using a very low and precisely controlled flow rate of the sample through the flow cell and by using a combination of two fluorescent dyes with different fluorescence emission characteristics, one of which has an affinity for labeled nucleic acids and the other for labeled proteins. The dyes are non-specific for the virus type, but the identification of simultaneous detection events of two different fluorescence emissions from the two fluorescent dyes can indicate that such non-associated viral particles have passed through the flow cell. Due to the nature of the dyes used for counting, Virus cytometry can detect the presence of free, non-associated viral particles (sometimes called virions) of a variety of viruses. Flow cytometry provides additional biologically relevant information.

[0011] The above-mentioned type of non-specific protein and nucleic acid dyes are fluorescent. The dye molecules have only a very weak fluorescence response in the free, unbound state, but when the molecular orientation becomes fixed in conjunction with the particle, the magnitude of the fluorescence response increases significantly. This increase in fluorescence response from the free, unbound state to the bound state can be an increase of more than one order of magnitude. This allows the strong fluorescence signal of the bound dye molecules to be identified from the background fluorescence of the unbound dye molecules, because the fluorescence response from the unbound dye molecules is much weaker.

[0012] However, in some cases, this flow cytometry technique has limitations. For example, this technique is not optimal for the assessment of non-enveloped viruses such as adenovirus or adeno-associated virus. The absence of readily available envelope proteins on the non-enveloped virus can significantly limit the accuracy of virus quantitative techniques. As another example, in some systems (such as baculovirus protein expression systems), target virus particles (such as baculovirus particles) can be present in a fluid comprising a high concentration of serum protein, which is generally from fetal bovine serum (FBS). When using the BacMam expression vector system, this may be the case. The presence of these high serum protein concentrations significantly complicates the distinction between the fluorescent signal of the viral protein from the dyeing and the high-level background fluorescent signal of the serum protein from the dyeing, which can significantly adversely affect the accuracy of virus quantitative.

[0013] About influenza virus, it is very common to produce influenza virus in eggs. This is the main technology of producing influenza virus in the vaccine industry and / or in research purposes. Due to the existence of the attached material of the egg collected together with the influenza virus of results, the flow cytometry differentiation of the influenza virus particles of results is significantly complicated. This attached material can include, for example, cell debris, chicken embryo fragments, bacteria, protein aggregates, lipids, lipid assemblies, lipid-protein assemblies, lecithin, lipid-protein aggregates, liposomes, ribosomes, vesicles, protein-nucleic acid complexes or other materials. Many of these attached materials can include proteins or nucleic acid components combined with corresponding staining agents, which can produce higher background signal levels, which can make the differentiation of the influenza particles of targeting and the fragment signals of dyeing complicated. The influenza virus samples of results can be purified to a certain extent to remove at least some such interference attached materials, which can improve the flow cytometry operation, but this purification process may be time-consuming and can increase a large amount of expenses, particularly if it is necessary to purify the influenza virus samples of results with a very high degree to prepare for flow cytometry assessment, and even in the purification of a significant degree, there is still this interfering substance. Some particularly difficult accessory materials are lutein, which when present in significant concentrations can adversely interfere with the binding of nucleic acid stains to influenza virus particles of interest, which can result in significant undercounting of influenza virus particles.

[0014] Given the importance of applications involving these viruses and viral agents, and the often potential toxicity of viral agents, rapid, inexpensive, and reliable quantification techniques will be needed. Summary of the invention

[0015] Flow cytometry is relatively new as a useful technique for evaluating viral particles. Most flow cytometric evaluations of biological materials involve detecting and studying the properties of particles that are approximately the size of cells derived from multicellular organisms or larger organisms. Such particles can be individual cells or microspheres (usually made of materials such as latex or polystyrene), which are functionalized to have an affinity for binding to smaller biological units of interest. Such microspheres are sometimes also called beads or microbeads. The presence of cells or microsphere particles is usually identified in flow cytometry by detecting and analyzing the scattered light emitted from the flow cell. Various fluorescent staining techniques have also been used to provide additional information about some specific biological characteristics of such particles, such as specific biological properties of the cells detected or the biomaterials bound to the microspheres. Light scattering detection of cells or microsphere particles is supplemented by also detecting specific fluorescent emission from fluorescent dyes. Some fluorescent dyes include fluorescent molecules that are bound to antibodies with binding capacity for specific epitopes of interest for evaluation. However, these dyes are often fluorophores that exhibit high levels of fluorescent response regardless of whether they are bound to particles. By flow cytometry effectively quantitative virus-size particles in fluid samples, it is necessary to calculate each non-associated particle of virus size, measure sample flow rate and calculate the concentration of virus size particles according to the measured particle number and the measured sample flow rate. Different from fluorescent dyes, the existence of background signals from unbound fluorophore dyes is a major problem. Some techniques can be used to ensure that the detected fluorescent signal is associated with cells or microspheres of interest, rather than from the debris of dyeing or the free unbound fluorescent dye molecules that may remain in the solution. After dyeing particles with the required fluorescent dye, particles can be separated from the liquid containing residual fluorescent dye molecules in the solution, such as by filtering or by accelerating sedimentation, such as by centrifugation and decantation. Then the separated cells or microsphere particles are resuspended in the fresh suspension that does not contain unbound fluorescent dyes. In addition, time-dependent analysis can be performed to identify the occurrence of simultaneous events of light scattering detection indicating the presence of cells or microsphere particles and fluorescence emission detection indicating the presence of fluorescent dyes, which helps to ensure that the detected fluorescent signal is actually related to the property of the biomaterial of cells or microspheres.

[0016] However, it has been found that flow cytometry quantification of viral particles can be performed using fluorescent antibody stains without particle identification by light scatter detection, without separation of stained viral particles from a fluid with residual unbound stain after viral particle staining, and without the need for simultaneous detection of nonspecific protein and nucleic acid stains. This facilitates the practical use of fluorophore antibody stains to detect viruses for virotherapy and other applications, without complicating identification of viral size particles by light scatter detection or simultaneous detection of nucleic acid and protein fluorescent stains, and without removing stained particles from residual unbound antibody stain fluorophores in a fluid sample after staining. This is significant because the viral particles are very small in size.

[0017] One aspect of the present invention is a method for evaluating a sample of biological material for non-associated virus-sized particles having a specific epitope (i.e., specific antibody binding capacity). The specific antibody-binding activity may indicate the type of particle, such as the virus type of a virus or virus-like particle or the type of an exosome or other nanoparticle. The method includes subjecting a fluid sample containing at least a portion of the sample of biological material to be evaluated to flow cytometry, wherein the fluid sample contains a fluorescent antibody stain capable of directly or indirectly binding to a specific epitope. The flow cytometry may include passing the fluid sample through a flow cell of a flow cytometer; subjecting the fluid sample flowing through the flow cell to excitation radiation capable of causing a fluorescent emission response from the fluorescent antibody stain; and detecting radiation from the flow cell within the wavelength range of the fluorescent emission and evaluating the detected radiation to identify a detection event indicating that a non-associated labeled particle of the virus size passes through the flow cell, the non-associated labeled particle of the virus size comprising the virus-sized particle having the epitope and a fluorescent antibody stain. Each such detection event corresponds to a single such non-associated labeled particle.

[0018] Many feature improvements and additional features are applicable to this aspect and other aspects of the present invention. These feature improvements and additional features can be used alone or in any combination in the theme of this aspect or any other aspect of the present invention. Therefore, each of the following features can be used together with any other feature of this aspect or the combination of features or any other aspect of the present invention, but not necessarily.

[0019] The main application area of ​​the method of this aspect is the field of influenza virus, including, for example, common in the vaccine industry, in the case where the sample to be evaluated contains interfering accessory substances (including any such accessory substances mentioned above) from eggs. The vaccine industry is constantly developing and manufacturing new vaccine products to address the rapid evolution and emergence of influenza virus strains, and there is a significant demand for fast, low-cost and reliable technology for the presence of virus-sized particles of quantitative influenza virus types. This demand, for example, extends to quantifying influenza virus particles and other virus particles, such as virus-like particles of influenza virus types. However, variations of the method of this aspect are also applicable to other viruses and viral reagent applications, including as further discussed below.

[0020] The method may include preparing a fluid sample comprising a biological material to be evaluated for the presence of non-associated particles of viral size and at least one fluorescent antibody stain capable of binding directly or indirectly to the non-associated viral size particles via an epitope, thereby forming non-associated labeled particles of viral size detectable during flow cytometry. Preparing the fluid sample may include mixing the biological material to be evaluated, or a portion thereof, with the fluorescent antibody stain. Subjecting the fluid sample to flow cytometry may include flowing the fluid sample through a flow cell of a flow cytometer under flow conditions so that the viral size particles pass alone through the flow cell.

[0021] The non-associated virus-sized particle targeted for detection can be any virus-sized particle including an epitope of interest. The particle can have multiple epitopes, at least one of which is of interest for particle evaluation. Multiple epitopes can be of interest on the same virus-sized particle of interest, and can be targeted using a corresponding number of different fluorescent antibody stains. Examples of some non-associated virus-sized particles that can be targeted for detection include virus particles (including viruses and particles such as virus-like particles with viral properties) and exosomes. The discussion provided by the present invention is primarily illustrated by reference to virus particles, but the principles discussed are also applicable to other virus-sized particles (e.g., exosomes and other nanoparticles) with specific epitopes that can be targeted for detection.

[0022] The significant advantage of this method is that it is not necessary to remove the unbound fluorescent antibody staining agent remaining in the solution from the fluid sample before flow cytometry. The remaining unbound fluorescent antibody staining agent will need troublesome and time-consuming processing, such as ultracentrifugation, from the interested virus size particles of the fluorescent labeling for evaluation. This is significantly different from separating antibody staining agents from larger labeled particles such as cells or immunoassay beads in previous applications, and separating fluorescent antibody staining agents from virus size particles is significantly more complicated, time-consuming and expensive than separating in this larger particle background. In a preferred embodiment, preparing the fluid sample includes, after mixing, before flow cytometry, not removing unbound fluorescent antibody staining agents from the fluid sample, i.e., not being bound to the fluorescent antibody staining agents (such as free in solution) in the particles of non-associated labeling. In other words, when the fluid sample is carried out to flow cytometry, the residual unbound fluorescent antibody staining agent from the mixing step can be maintained in the fluid sample, thereby being retained in the fluid sample. This unbound fluorescent antibody staining agent can represent most of the fluorescent antibody staining agents mixed with biomaterials during the mixing step. However, an important consideration for flow cytometry performance is to control the concentration of the residual unbound fluorescent antibody stain molecules in the solution so that the fluorescence emission signal from such unbound fluorescent antibody stain molecules does not cover or affect the fluorescence emission signal from the non-associated labeled virus-sized particles and prevent the emission signal of the non-associated labeled particles from changing. In some preferred embodiments, the fluid sample fed to the flow cytometer can have a concentration of the unbound fluorescent antibody stain (not bound in the non-associated labeled particles) of 0.25 μg / ml, 0.5 μg / ml, 0.7 μg / ml, 1 μg / ml, 2 μg / ml, 3 μg / ml or 5 μg / ml, and an upper limit of 10 μg / ml, 8 μg / ml, 7 μg / ml, 6 μg / ml, 5 μg / ml, 4 μg / ml, 3 μg / ml, 2.5 μg / ml or 2 μg / ml, wherein the upper limit is greater than the lower limit. When the fluid sample includes multiple different types of fluorescent antibody stains, this concentration of residual unbound fluorescent antibody stains can be applied to the concentration of each individual fluorescent antibody stain type and / or the combined concentration of a portion or all of the fluorescent antibody stains. This concentration of residual unbound fluorescent antibody stains of about 2, about 2.5, or about 3 μg / ml or within a relatively narrow range (e.g., within 0.5 μg / ml) above or below 2, 2.5, or 3 μg / ml can be preferably used in many embodiments.In some preferred embodiments, the total concentration of the fluorescent antibody stain (including residual, unbound fluorescent antibody stain and fluorescent antibody stain bound in non-associated labeled particles) of the fluid sample fed to the flow cytometer can be as follows: the lower limit of the range is 0.25 μg / ml, 0.5 μg / ml, 0.7 μg / ml, 1 μg / ml, 2 μg / ml, 3 μg / ml or 5 μg / ml and the upper limit is 10 μg / ml, 8 μg / ml, 7 μg / ml, 6 μg / ml, 5 μg / ml, 4 μg / ml, 3 μg / ml, 2.5 μg / ml or 2 μg / ml, wherein the upper limit is greater than the lower limit. Such concentrations of fluorescent antibody stains of about 2, about 2.5 or about 3 μg / ml or above or below 2, 2.5 or 3 μg / ml in a relatively narrow range (e.g., within 0.5 μg / ml) can be preferably used in many embodiments. When fluid sample comprises multiple different types of fluorescent antibody stain, this total concentration of fluorescent antibody stain can be applied to the total concentration of every kind of independent fluorescent antibody type and / or the combined concentration of a part or all of fluorescent antibody stain.About 2, about 2.5 or about 3 micrograms / ml or in relatively narrow range (for example, within 0.5 micrograms / ml) higher or lower than this concentration of 2,2.5 or 3 micrograms / ml can be preferably used for many embodiments.As will be understood, the optimum concentration for this total concentration of fluorescent antibody stain or the concentration of residual non-associated antibody stain can be different between specific applications, but the prescribed range is usually applicable to many applications.The optimum concentration for specific application can depend on following variable: for example, the concentration of the non-associated virus size particles of targeting, the amount of the epi-position on this non-associated particle (the number of binding sites for fluorescent antibody stain) and the affinity of fluorescent antibody stain combined with the epi-position on the non-associated particle. In some preferred embodiments, the fluid sample fed to the flow cytometer may have a concentration of unassociated labeled particles of 1 x 10 at the lower end of the range. 5 , 1x 10 6 or 1x 10 7 particles / ml, and the upper limit is 1x 10 9 , 1x 10 8 or 1x10 7Particles / ml, provided that the upper limit is greater than the lower limit. When the fluid sample includes a plurality of different types of particles with different epitopes (detected by different types of fluorescent antibody stains), this concentration of non-associated labeled particles can be applied to the concentration of non-associated labeled particles of each particle type and / or the combined concentration of some or all non-associated labeled particles of all particle types to be detected. In some preferred embodiments, when the fluid sample is fed into the flow cytometer, substantially all particle types to be detected are non-associated labeled virus-sized particles. In some preferred embodiments, when a detection event indicating non-associated labeled virus-sized particles in flow cytometry occurs during flow cytometry, there are many such detection events per minute, with a range lower limit of 300, 1000 or 10,000 such detection events per minute, and an upper limit of 325,000 or 100,000 such detection events per minute. As will be appreciated, the sample fluid needs to be run at various dilution levels to obtain the desired concentrations of unassociated labeled particles and fluorescent dyes (bound and unbound unassociated labeled particles) and appropriate counts of detection events per minute.

[0023] Another advantage of the methods disclosed herein is that flow cytometry can be used to identify specific types of virus-sized particles (e.g., as indicated by specific antigen binding capabilities) without detecting light scattering to identify the presence of particles, such as when identifying the type of virus in a host cell or the type of virus attached to a microsphere. In a preferred embodiment, flow cytometry does not include (is absent from) detecting light scattering, and may include only detecting the fluorescence emission of a fluorescent stain or only detecting the fluorescence emission of one or more fluorescent antibody stains.

[0024] Fluorescent antibody stains can include one or more fluorescent components connected to an antibody molecule, which specifically binds to the epitope of a target particle of a virus type. These fluorescent components can be any component with fluorescent activity, to act as a fluorescent marker attached to an antibody molecule. The connection of the fluorescent component to the antibody molecule can be direct or indirect. The connection can be by chemical bonds or other attachment mechanisms. Some examples of fluorescent components that can be included in fluorescent antibody stains include fluorophores (fluorescent compounds), fluorescent conductive nanocrystals (quantum dots), fluorescent polymers, fluorescent phycobilichromes, and recombinant fluorescent proteins. The description here is mainly exemplified by the use of reference fluorophores, but the description is also applicable to other fluorescent components that can be attached to antibody molecules. In the case of fluorophores, the antibody molecules of each fluorescent antibody stain of the fluorescent antibody stain can preferably include an average number (F / P ratio) of attached fluorophore groups (dye molecules) with a lower limit of 3, 4 or 5 and an upper limit of 10, 9, 8 or 7, wherein the range of 5 to 7 is preferred for many applications. The antibody molecules of the fluorescent antibody stain can be monoclonal or polyclonal. In many cases, monoclonal antibodies can be preferably used for targeted detection of many virus types. However, due to the rapid evolution of some viruses, polyclonal antibodies may be preferred for some applications of the assessment for various viral serotypes. The following is exactly this situation, such as influenza virus (particularly influenza A virus) and other viruses that may be easy to evolve rapidly, such as being easy to rapid genetic drift, genetic drift and recombinant viruses, such as RNA viruses. The virus type targeted for assessment can be related to any type of virus. Except influenza virus, some example virus types, including baculovirus, adenovirus, enterovirus, adeno-associated virus (AAV) or norovirus and their specific serotype. Virus type refers to a specific category for the viral attribute detected and differentiated, and it can be a family, subfamily, species or serotype level or any identifiable subset of the foregoing. As some examples, the target virus type can include a single specific serotype, or can include multiple serotypes, which share a common antigenic attribute to interact with a fluorescent antibody stain (for example, including multiple serotypes of a common epitope combined with identical monoclonal fluorescent antibody stain). In the application of assessing the presence of two different target virus types in a fluid sample, different virus types can represent, for example, different families, subfamilies, genera, species or serotypes. One such example may be the assessment of the presence of two different serotypes of influenza virus (as different virus types). Another such example may be the assessment of different virus species as two different virus types. Another such example may be the assessment of virus-like particles of two different virus families, such as baculovirus and a different virus family (e.g., influenza virus, adenovirus, adeno-associated virus).It should be understood that the fluorescent antibody stain with polyclonal antibodies will include a variety of different staining antibody molecules, each of which is combined with a different epitope of the target virus type, such as with different serotypes (e.g., different types, subtypes and / or strains of influenza virus). A preferred example of using polyclonal antibodies is to assess influenza virus types across multiple serotypes (e.g., polyclonal antibodies with antibody molecules that bind to epitopes of both A and B influenza viruses, or polyclonal antibody molecules that bind to epitopes of different subtypes and strains of A influenza virus and / or different strains of B influenza virus).

[0025] As will be appreciated, influenza virus includes three types: Type A, Type B and Type C, all of which have a virus particle size generally within the range of about 80 nanometers to 120 nanometers. The virus type of target influenza virus can include any one of these three types or more than one. Type A influenza virus includes many different serotypes, and is prone to genetic drift and occasional rapid genetic drift. Therefore, when the virus type of target influenza virus includes Type A influenza virus, polyclonal fluorescent antibody staining agents are generally beneficial. Similarly, when Type A and Type B influenza virus serotypes are targeted for analysis, the use of polyclonal fluorescent antibodies is generally beneficial. However, in the case where analysis is for specific Type A serotypes or specifically for Type B influenza virus (which has a single specific target epitope), monoclonal fluorescent antibody staining agents may be preferably used. Type C influenza virus may also be targeted for evaluation, such as for research purposes.

[0026] In some applications, virus-sized particles of the baculovirus type may be targeted for evaluation as the sole target virus type, or in applications that also involve targeting another virus type, such as virus-like particles of other virus types being simultaneously targeted for evaluation.

[0027] Baculovirus is a family of rod-shaped viruses (Baculoviridae) up to 300 nm long, which are particularly useful for producing recombinant proteins. Baculoviruses are commonly infected and replicated in insect cells, and the use of genetically modified baculovirus expression vectors to express recombinant proteins in insect cell systems is a well-known technique. Baculoviruses can also be genetically modified to include mammalian promoters to drive recombinant protein expression in mammalian cells. The modified baculovirus system including a mammalian promoter that can be used to transfer inserted genetic material by transduction into mammalian cells is commonly referred to as the "BacMam" system for transferring baculovirus genes into mammalian cells.

[0028] Baculovirus can also be used to produce virus-like particles, which can include multiple viral proteins. Exemplary virus types that can be expressed in such virus-like particles include influenza virus, adenovirus and adeno-associated virus. Depending on the processing stage in a specific process or process, baculovirus can be a desired product or an undesirable pollutant. In either case, accurate monitoring and quantification of baculovirus at various points in the production operation are important for process and product control. As mentioned above, when using the prior art of a combination of non-specific fluorescent proteins and nucleic acid staining, the presence of fetal bovine serum (FBS) in some baculovirus protein expression systems (e.g., BacMam systems) can significantly complicate the distinction between the fluorescent signal of the stained protein in the virus particle of interest and the high-level background fluorescent signal of the serum protein from staining.

[0029] Fluorescent antibody stains can bind to viral particles directly or indirectly via an epitope. Direct binding via an epitope refers to binding of a site on the antibody portion of the fluorescent antibody stain to the epitope. Indirect binding via an epitope refers to the presence of an intermediate binding unit between the epitope and the fluorescent antibody stain. For example, an intermediate binding unit can be a different antibody (different from the antibody of the fluorescent antibody stain) that directly binds to the epitope, and the fluorescent antibody stain binds to the antibody, thereby binding the fluorescent antibody stain to non-associated labeled particles.

[0030] Fluorescent antibody stains can include a fluorescent component, such as a fluorophore, which is excited by any convenient excitation radiation and has an appropriate Stokes shift between the absorption spectrum of the excitation radiation and the emission spectrum of the fluorescent emission. The fluorophore can be provided by a fluorescent dye molecule that is connected or conjugated to another molecule in the form of a fixed, highly fluorescent state. The fluorescent dye can be conjugated directly to the antibody, or it can be conjugated to an additional component that is then connected to the antibody (e.g., biotinylated fluorescent antibody stains discussed below).

[0031] The excitation radiation of fluorescent antibody stain or other fluorescent stain that can also be used can be within any suitable one or more wavelength ranges of one or more fluorescent stains used. When using multiple fluorescent dyes, it is preferred that the emission spectra of different fluorescent stains do not overlap or only overlap to a minimum extent, thereby facilitating separate detection. The excitation radiation can generally be in a visible or near-visible spectrum (e.g., ultraviolet to near infrared). Some example light sources of excitation radiation include LEDs and lasers that provide narrow spectrums. Various small lasers can be used as excitation radiation sources. Some exemplary lasers are green lasers, such as green He-Ne or Nd:YAG lasers. Other possible lasers for providing excitation radiation are discussed, for example, in Methods in Molecular Biology, Vol. 263, Flow Cytometry Protocols, 2nd Edition, Hawley, Teresa S. and Haley Robert G., eds., Humana Press, 2004, Chapter 23 "Small Lasers in Flow Cytometry", Telford, William G., pp. 399-418; Methods in Cell Biology, Vol. 102, Recent Advances in Cytometry, Part A: Instrumentation, Methods, Darzynkiewicz, Zbigniew et al., eds., Elsevier, 2011, Chapter 15 "Lasers in Flow Cytometry", Telford, William G., pp. 375-407; and Telford, William G. et al., Supercontinuum white light lasers for flow cytometry, Cytometry A. 2009May,75(5):450-459.doi:10.1002 / cyto.a.20687.

[0032] In some preferred embodiments, when two or more different fluorescent stains are used in a single fluid sample, for example, when evaluating different biological material components (which may be different virus types), multiple fluorescent stains may preferably be excited by the same narrow spectrum excitation radiation, although in other embodiments, multiple excitation radiation sources or a single light source (e.g., an adjustable white light source) providing multiple excitation radiation spectra may be used, as long as the fluorescence emission responses of different fluorescent stains can be distinguished by the different excitation radiation spectra. Some exemplary excitation radiations for many applications may be narrow spectra including one of the following wavelengths: 350 nanometers, 405 nanometers, 488 nanometers, 532 nanometers, 543 nanometers, 561 nanometers, and 635 nanometers. The fluorescence emission spectrum may include any narrow spectrum, typically within the visible and near-visible spectrum. It is generally preferred that the fluorescence emission spectrum of a fluorescent stain (including a fluorescent antibody stain) has a significant Stokes shift of the peak wavelength relative to the peak wavelength of the excitation spectrum of the fluorescent stain. The Stokes shift of the wavelength may be at least 5 nanometers, at least 10 nanometers, at least 20 nanometers, or more. Many fluorescent stains have Stokes shifts in the range of 10 to 50 nanometers, although some may have larger Stokes shifts.

[0033] Some exemplary antibodies for fluorescent antibody staining of some virus types are shown in Table 1.

[0034]

[0035]

[0036] The antibody of the fluorescent antibody stain can be a pan-serotype antibody (binding to multiple serotypes). The polyclonal M149 product from Takara is a rabbit polyclonal antibody against human influenza A and B, which is a pan-serotype across multiple influenza virus serotypes (including multiple serotypes of influenza B virus and influenza A virus). The monoclonal antibody of the fluorescent antibody stain can be serotype-specific, or can be pan-serotype to a certain extent. For example, the ADK8 / 9 listed in Table 1 is a pan-serotype of AAV-8 and AAV-9 serotypes. As another example, for adenovirus, the antibody in the fluorescent antibody stain, for example, binds to the capsid protein present between multiple serotypes. For example, 8C4 listed in Table 1 is this case, which binds to the hexon protein present between multiple adenovirus serotypes.

[0037] A variety of fluorophores can be used in fluorescent antibody stains. The fluorophore can be directly attached to the antibody or attached via a linking group. Such a linking group can be a biotin-derived linking group on a biotinylated antibody, through which the fluorophore-conjugated streptavidin can bind to the antibody. For ease of reference, this fluorescent antibody stain with a fluorophore attached to a biotinylated antibody may be referred to as a biotinylated fluorescent antibody stain in the present invention. Table 2 shows some example fluorescent dye products in the Alexa Fluor product line (Life Technologies, Thermo Fisher Scientific) that can be used as fluorophores in conjugated form, as well as the peak excitation (absorption) wavelength and emission wavelength of the dye molecule conjugate. The Stokes shift of the conjugate is the difference between these wavelengths:

[0038]

[0039] Some example dyes used as fluorophores in conjugate form and with a green laser excitation light source (for various antibodies to produce fluorescent antibody staining) are shown in Table 3.

[0040]

[0041] Any of the exemplary dyes listed in Tables 2 and 3 or other dyes can be used with any of the exemplary antibodies listed in Table 1 in a fluorescent antibody stain.

[0042] Fluid sample can only include single fluorescent stain, which will be fluorescent antibody stain. In alternative embodiments, fluid sample can include multiple fluorescent stains (that is, two or more than two different fluorescent stains), at least one of which is fluorescent antibody stain. When using multiple fluorescent stains, two or more than two fluorescent stains can be fluorescent antibody stains and / or one or more than one fluorescent stains that can be other than fluorescent antibody stain, such as non-specific fluorescent stain. An example of this non-specific fluorescent stain is a stain for marking nucleic acid. Non-specific fluorescent stain refers to a fluorescent stain that is not specific to virus type. An example of a nucleic acid non-specific fluorescent stain that can be excited by a green laser light source is POPO-3 from Life Technologies (Thermo Fisher Scientific). When using multiple different fluorescent antibody stains, different fluorescent antibody stains can be directed to identify the virus particles of different virus types, in which case each different fluorescent antibody stain can be combined with different virus particles of different virus types to form different non-associated labeled particles. Flow cytometry can include detecting radiation from a flow cell at different wavelength ranges for different fluorescent antibody stains to identify detection events indicative of particle types with different non-associated markers (which indicates the presence of different virus types) passing through the flow cell.

[0043] Fluorescent antibody staining agents and biomaterials for evaluation can be mixed in a liquid medium, such as in a buffered aqueous liquid. During mixing, fluorescent antibody staining agents can be provided in the form that fluorophores have been connected to antibodies, or fluorescent antibody staining agents can be formed in situ by precursor components provided to mixing during mixing. Fluorescent antibody staining agents can be formed from the solution of these precursors during mixing, then attached to non-associated particles, and / or can be formed on non-associated particles to form particles of non-associated labels. For example, in the case of biotinylated fluorescent antibody staining agents, biotinylated antibody staining agents can be prepared in advance and provided to the mixture in a pre-prepared state, such as a state dispersed in a buffer solution, or the precursors of biotinylated antibody staining agents can be provided to mixing respectively, and can be contacted for the first time during mixing so as to form biotinylated antibodies in situ. As an example, pre-prepared biotinylated antibodies and pre-prepared fluorophores: streptavidin conjugates can be provided to the mixing step separately, such as in an independent buffer solution formulation. The pre-prepared biotinylated antibody and the pre-prepared fluorophore:streptavidin conjugate can then react to form a biotinylated fluorescent antibody stain. This reaction can occur before the antibody is bound to the non-associated particles, and / or this reaction can occur after the biotinylated fluorescent antibody has been bound to the non-associated particles, in which case the biotinylated fluorescent antibody stain can be formed directly on the unassociated particles, thereby forming non-associated labeled particles and simultaneously forming the biotinylated fluorescent antibody stain. When these precursors are provided separately to the mixture, the precursors can be added in appropriate proportions to provide the resulting fluorescent antibody stain at the desired concentration, preferably without a large amount of residual non-associated fluorophore:streptavidin conjugate, which will significantly increase additional background fluorescence.

[0044] The virus-sized particles targeted for detection can be virus particles. Virus particles refer to individual particles of a virus (e.g., virions) or virus-like particles, and virus type refers to a specific type of virus or virus-like particle related to that type of virus. As will be understood, virus-like particles are particles that are similar to viruses but are not infectious due to the lack of complete viral composition (e.g., viral genetic material). The virus-sized particles targeted for detection can be exosomes or other nanoparticles with epitopes for binding to antibodies.

[0045] Virus size particles or virus size particles refer to particles of the order of magnitude of a single, free virus particle or virion, typically in the range of tens of nanometers to hundreds of nanometers. In some embodiments, the size range that virus size particles can have is 10 nanometers, 20 nanometers, 40 nanometers, 60 nanometers, or 80 nanometers at the lower limit, and 2 microns, 1 micron, 600 nanometers, 300 nanometers, or 200 nanometers at the upper limit. In some embodiments, virus size particles can have any one or more of a length dimension, a diameter dimension, or a maximum cross-sectional dimension within the range. The so-called particle is non-associated, meaning that the particle is not part of a larger particle structure greater than the virus size, such as a non-associated particle not in a host cell, or not combined with a microsphere, or not part of an aggregate greater than the virus size. Relative to unlabeled virus size particles (e.g., unlabeled virions, exosomes, or virus-like particles), non-associated labeled particles will have a slightly larger size. Even with the bound fluorescent antibody stain, the non-associated labeled particles are viral sized and can generally have a maximum cross-sectional dimension greater than the maximum cross-sectional dimension of an unlabeled viral sized particle, which has a maximum cross-sectional dimension ranging from 10 nanometers, 20 nanometers, or 30 nanometers at the lower limit to 200 nanometers, 150 nanometers, 100 nanometers, 50 nanometers, or 25 nanometers at the upper limit, wherein the upper limit is greater than the lower limit. For example, a single antibody molecule having a size of about 5 to 10 nanometers can generally increase the maximum cross-sectional dimension of the labeled particle by a factor of two, or by about 10 to 20 nanometers, relative to the unlabeled viral sized particle. As will be appreciated, an indirectly bound antibody stain can increase the maximum cross-sectional dimension by a greater amount due to an intermediate binding group.

[0046] The biological material to be evaluated can be obtained from any source. Some example sources include: manufacturing operations (e.g., vaccine production) of culturing viruses; preparing genetically modified viral particles (e.g., virus-like particles) such as for alternative forms of vaccines, wherein genetically modified viruses are prepared for expression of recombinant proteins, or for delivery of genetic material for viral therapy; or preparing batches of purified virus-sized particles to test the exclusion limit (exclusion limit) in biological fluid manufacturing. The method can be associated with such a manufacturing operation or performed as part of it. The biological material can be the result of a previous treatment of the initial biological material, which can be a crude material that has been purified or otherwise treated to prepare a more suitable sample for flow cytometry evaluation. The biological material can be provided for mixing with a fluorescent antibody stain in any convenient form, including in a buffered aqueous solution, such as a phosphate buffered solution, which can contain one or more additives or other reagents that can be used for processing. Similarly, fluorescent antibody staining can be provided in any convenient form, including in a buffered solution, such as a phosphate buffered solution or other buffered solution. The biological material can be provided in a purified form, such as can be produced by a purification process. This purification process may be as disclosed in International Patent Publication No. WO2014 / 210370A1, the entire contents of which are incorporated herein by reference. The biological material may be provided for mixing with a fluorescent antibody stain in a Tris-HCl buffer solution (as disclosed in WO2014 / 210370A1 for flow cytometry), or a different buffer solution may be used. The flow cytometer may be, for example, a Virus 2100 Flow Cytometer, or preferably Virus 3100 flow cytometer (ViroCyt, Inc.). Such flow cytometers are specifically designed to operate at very low sample flow rates to assess the presence of virus-sized particles in fluid samples. Although less preferred, other flow cytometers can also be used that allow virus-sized particles to be concentrated sufficiently in the center of the fluid sample stream for study in the flow cell. Some examples of other flow cytometers equipped with a green laser source for excitation radiation are NxT (ThermoFisher Scientific), Space (Sysmex) and S1000EXi (Stradedigm). Some examples of other flow cytometers that may include excitation radiation sources other than green lasers are ACSCalibur TM (BectonDickinson), BD LSRFortessa TM (Becton Dickinson), BD FACSCanto TM(Becton Dickinson), FACSVerse (Becton Dickinson), Gallios TM (Beckman Coulter), CyAn TM ADP (Beckman Coulter), SE520EXi (Stratedigm) and SP6800 (SONY). As described above, the biological material in the fluid sample may be in a purified form for enhanced flow cytometry evaluation, and it may be the result of purifying a crude sample of the biological material according to the method disclosed in WO2014 / 210370A1.

[0047] The preparation of fluid sample can include the crude sample of purifying biomaterial before the biomaterial for assessment is mixed with fluorescent antibody stain, to prepare the biomaterial for the fluid sample for flow cytometry. Purification can include filtering out the particles of larger size impurities in the crude sample. This larger size impurity can include particles larger than the size of the virus. This larger size impurity can include, for example, cell debris, bacteria, mycobacterium protein aggregates, lipids, lipid assemblies, lipid-protein assemblies, lecithin, lipid-protein aggregates, liposomes, ribosomes, vesicles, protein-nucleic acid complexes or other materials. Filtration can include filtering with the following filter separation size or filtration size: no more than 2 microns, no more than 1.5 microns, no more than 1.3 microns, no more than 1 micron, no more than 0.9 micron, no more than 0.8 micron or no more than 0.75 micron of filtration. Separation size can be usually at least 0.05 micron, at least 0.1 micron, at least 0.3 micron, at least 0.4 micron, at least 0.5 micron, at least 0.6 micron or at least 0.7 micron. Purification can include chromatography to remove at least a portion of smaller sized impurities (which can be smaller than the virus size). Such smaller sized impurities can include, for example, proteins and / or nucleic acids, and substances derived from viruses, such as fragments or fragments from viruses. Chromatographic removal can include spin chromatography in a centrifuge. Spin chromatography can include centrifuging the sample to be purified in the presence of a chromatographic medium that captures smaller sized impurities, which can be in a buffered solution. The supernatant containing the residual biological material can be further processed, for example by filtering, or provided directly to be mixed with a fluorescent antibody stain.

[0048] In other embodiments, the fluid sample may include a crude form of a biological material sample that has not been purified or has not been purified to a significant degree. Even with a crude sample of the biological material, the specificity of the fluorescent antibody stain peak signal of the labeled virus-sized particles can be distinguished from the background reading.

[0049] In some preferred embodiments, flow cytometry can include flowing a fluid sample through a flow cytometer flow cell at a very low fluid sample flow rate. Such a sample fluid flow rate can be in the range of 250-3000 nanoliters per minute. As described above, a flow cytometer with a larger flow rate can also be used, which is able to concentrate virus-sized particles in the center of the fluid sample flow for study in the flow cell. Such a flow cytometer can, for example, have a fluid sample flow rate of up to 1 ml / min. In a preferred embodiment, flow cytometry can include focusing the fluid sample flow through a fluid dynamic force with a sheath fluid, and flowing the fluid sample and sheath fluid through a flow cell. In addition, in some more preferred embodiments, flow cytometry or a flow cytometer used by the flow cytometer (e.g., Virus 3100 flow cytometer) can be used to evaluate the particle attributes of the fluorescence emission signal as described below: International Patent Application No. PCT / US2015 / 033907 (Publication No. WO2015 / 187783), entitled FLOW CYTOMTER PEAK SIGNAL IDENTIFICATION EMPLOYING DYNAMIC THRESHOLDING, the entire contents of which are incorporated herein by reference. In this way, the peak signal threshold for identifying particle counts using a dynamic threshold determination is evaluated, and it is particularly advantageous for use with the methods of the present disclosure to quantitatively evaluate labeled non-associated virus-sized particles. It has been found that Virus The 3100 flow cytometer has the following advantageous capabilities: to distinguish the fluorescent response signal from non-associated labeled virus-sized particles from the background signal of residual unbound fluorescent antibody stain; to identify fluorescent response detection events indicative of non-associated labeled virus-sized particles passing through the flow cytometer flow cell; to count such non-associated labeled particles in the fluid sample based on these detection events; and to calculate and display the concentration of non-associated labeled particles in the flow sample in real time relative to the fluid sample passing through the flow cell. Virus The 3100 flow cytometer monitors, measures and carefully controls the flow rate of the fluid sample flowing to the flow cell and, unlike other flow cytometers, uses the integrated flow rate measurement data over time to determine the volume of sample fluid passing through the flow cell for the purpose of concentration calculation. Additional information is provided in WO2010 / 132053, the contents of which are incorporated herein by reference.

[0050] In some embodiments, the flow cytometry may include counting detection events as each occurrence of a non-associated labeled particle passing through the flow cell to determine a count of non-associated labeled particles in a volume of a fluid sample passing through the flow cell; determining a volume of the fluid sample passing through the flow cell corresponding to the count; and using the count of non-associated labeled particles to determine a concentration of non-associated labeled particles in the volume of the fluid sample passing through the flow cell. Such counting may be performed in real time relative to the detection of radiation corresponding to the detection event, and the concentration determination may also be performed in real time relative to the volume of the fluid sample passing through the flow cell. Determining the volume of the fluid sample passing through the flow cell may include measuring the flow rate of the fluid sample flowing into the flow cell in real time with a flow sensor and integrating the resulting flow rate measurement data over time. Detection events indicating the presence of non-associated labeled particles passing through the flow cell may be identified without being associated with light scattering detection information. Flow cytometry operation control and data acquisition and analysis (e.g., identifying detection events, counting, determining volume, determining concentration, flow rate measurement data, integrating measured flow rate data) may be performed by an electronic controller, such as using a Virus 3100 flow cytometer.

[0051] The fluid sample may include a variety of fluorescent stains (two or more fluorescent stains), at least one of which is a fluorescent antibody stain. In some embodiments, the fluorescent stain may be a first fluorescent stain with a first fluorescent emission, and the fluid sample may contain different second fluorescent stains with different second fluorescent emissions (and may also have different third or even more different fluorescent stains). The first and second fluorescent emissions may be detected separately. The first detection event for the first fluorescent emission may indicate a first particle property (e.g., the presence of an epitope), and the second detection event for the second fluorescent emission may indicate a second particle property (e.g., the presence of different epitopes or some other properties). The different properties of the first and second detection events may be related to the two properties present on a single virus-sized particle (in this case, the first and second detection events will coincide with the time of a single particle passing through a flow cell), or may be related to each property present on different particles (in this case, the first and second detection events will not coincide in time). Such first and second fluorescent stains may be excited by the excitation radiation of the same wavelength, or may not be excited, although for simplicity of operation, it is convenient to excite both fluorescent stains by the excitation radiation of the same narrow spectrum.

[0052] In some embodiments, the first fluorescent stain can be a fluorescent antibody stain, and the second fluorescent stain can be a nucleic acid stain, which can be a non-specific fluorescent stain. The detection event for the second fluorescent emission can indicate the passage of virus-sized particles containing nucleic acids stained with fluorescent nucleic acid stains. The results of the separate detections of the first and second fluorescent stains can be compared to identify the occurrence of the first detection event that coincides with the second detection event in time, which can further indicate that the particles of the non-associated markers containing both epitopes and nucleic acid properties pass through the flow cell, for example, it can indicate complete viral particles. The comparison of the first and second detection events can optionally or additionally include the occurrence of the first detection event that does not coincide with the second detection event in time, which can, for example, indicate virus-like particles or exosomes (or other nanoparticles) with epitope properties but not nucleic acid properties due to the absence of genetic material. The comparison of the first and second detection events can optionally or additionally include the occurrence of the second detection event that does not coincide with the first detection event in time, which can, for example, indicate exosomes (or other nanoparticles) containing nucleic acid properties but not containing epitope properties.

[0053] When using multiple fluorescent stains, there will be multiple fluorescent antibody stains. For example, a first fluorescent antibody stain with a first fluorescent emission can bind to a first epitope, and a different second fluorescent antibody stain with a second fluorescent emission can bind to a different second epitope. A third or more additional fluorescent antibody stains and / or one or more non-specific stains (e.g., non-specific nucleic acid stains) can also be used, although the flow cytometer used will need to have the ability to distinguish all different fluorescence emission spectra. The first and second fluorescent emissions can be detected separately. The first detection event of the radiation of the first fluorescent emission can indicate the passage of a non-associated labeled virus-sized particle including a virus-sized particle containing the first epitope, and the second detection event of the radiation of the second fluorescent emission can indicate the passage of a non-associated labeled virus-sized particle including a virus-sized particle containing the second epitope. In the case where the virus-sized particle has the first and second epitopes at the same time, the first and second detection events will overlap in time, and when there are two different types of virus-sized particles, one with the first epitope and the other with the second epitope, the first and second detection events will not overlap in time. For example, a first epitope can indicate a particle of a first virus type, and a second epitope can indicate a particle of a second, different virus type. Alternatively, both the first and second epitopes can indicate the same virus type, such as when a virus particle contains both the first and second epitopes. In the case where both the first and second epitopes can indicate the same virus type, the virus type can be, for example, any of these example virus types.

[0054] In order to obtain more details about the content of the biomaterial sample to be evaluated, different parts of the sample can be evaluated separately by flow cytometry, wherein different fluorescent antibody stains are used in different fluid samples evaluated by different flow cytometry. In this way, multiple parts of the biomaterial sample can be processed to prepare the matrix of different fluid samples for flow cytometry, using different fluorescent stain combinations to test different combinations of particle properties in the biomaterial sample. Each different fluid sample can, for example, contain fluorescent antibody stains and non-specific fluorescent stains (e.g., nucleic acid stains) and / or with different combinations of multiple fluorescent antibody stains. Such matrix-type evaluation can, for example, be used to prepare and test one or more than one differently labeled fluid samples by flow cytometry to evaluate the presence of product particles of the desired virus size and / or to evaluate whether there are pollutant particles of unwanted virus size.

[0055] Evaluation methods including flow cytometry can be part of or be performed in association with a method for manufacturing a product comprising virus-sized particles. Such manufacturing can include: generating virus-sized particles in a bioproduction operation; harvesting a crude product comprising virus-sized particles from the bioproduction operation; and purifying at least a portion of the crude product material to produce a purified product comprising virus-sized particles. Such a purified product can be a final product, or can be an intermediate product that can be further processed. Flow cytometric evaluation performed as part of or in association with manufacturing can include collecting a sample of biological material from a stage of the production process (at which stage viral particles are expected to be present in the biological material), and evaluating the sample for the presence of virus-sized particles having a specific epitope, including subjecting at least a portion of the sample to flow cytometry. Such evaluation including flow cytometry can, for example, include any of the features described or any combination of the features described above. Such manufacturing can include performing multiple collections to collect different samples of the biological material to be evaluated from multiple different stages of manufacturing, and performing an evaluation on each such collected sample of biological material to be evaluated, including flow cytometry. In this way, product yield and quality can be verified through various stages of the manufacturing process, and process problems can be quickly identified, analyzed, and corrective actions taken. For example, collection can be performed in a first stage during production or harvesting and in a second stage during or after purification.

[0056] Evaluation methods including flow cytometry may be performed in an environment that is not part of or associated with the manufacturing. For example, the methods may be performed in conjunction with research or diagnostic activities.

[0057] One application of the methods disclosed herein is to evaluate a biological material sample for virus-like particles when the biological material sample is suspected of containing virus-like particles. This may be the case, for example, during or in connection with an operation to manufacture virus-like particles or products containing virus-like particles, for example for use in vaccines or as carriers (vectors).

[0058] Another important application of the methods disclosed herein is the assessment of influenza virus in a sample of biological material. This may be the case, for example, during or in connection with a manufacturing operation in which influenza virus is prepared for use in the preparation of a vaccine.

[0059] Another important application of the methods disclosed herein is the assessment of baculovirus particles in a sample of biological material. This may be the case, for example, during or in connection with a manufacturing operation using baculoviruses to produce recombinant proteins or to produce virus-like particles.

[0060] Another important application of the method disclosed in the present invention is to evaluate the intact viral particles of biological materials. Such viral detection can be to evaluate viral contaminants and / or to evaluate the presence of desired viral products. In one variant, the virus can be a virus edited for viral therapy. Such a virus can be, for example, an anti-cancer oncolytic virus, which is a viral vector for gene therapy or immunotherapy.

[0061] Another important application of the method disclosed in the present invention is to evaluate the allochthon or other nanoparticles of biological material samples. The detection of such allochthon or other nanoparticles can, for example, help to identify the pollutants of allochthon or other nanoparticles or the presence of required allochthon or other nanoparticle products. Allochthon has become the source of false positive indications in the viral particle flow cytometry using a combination of fluorescent proteins and nucleic acid dyes, because such allochthon sometimes contains proteins and nucleic acids that can be stained and mistakenly identified as viral particles. In addition, allochthon or other nanoparticles can be independently used as research objects.

[0062] Another aspect of the invention is a composition in the form of a fluid preparation, such as a fluid sample in a preparation for flow cytometry assessment. The fluid preparation comprises:

[0063] Aqueous liquid medium;

[0064] Non-associated labeled virus-sized particles in an aqueous liquid medium at a concentration of 1 x 10 5 Up to 15x 10 9 non-associated labeled particles / ml, wherein each of the non-associated labeled particles comprises a virus-sized particle having a specific epitope and a fluorescent antibody stain specific for binding directly or indirectly to the epitope; and

[0065] The concentration of the fluorescent antibody stain in the unassociated state (not bound to the unassociated labeled particles) in the aqueous liquid medium ranges from 0.25 (or more) μg / mL to 10 (or less) μg / mL.

[0066] Many feature improvements and additional features are applicable to this aspect and other aspects of the present invention. These feature improvements and additional features can be used alone or in any combination in the theme of this aspect or any other aspect of the present invention. Therefore, each of the following features can but not necessarily be used together with any other feature of this aspect or the combination of features or any other aspect of the present invention.

[0067] Such a fluid formulation can be or have any one or more of the characteristics described with respect to the fluid sample of the method aspects. The aqueous liquid medium, the non-associated labeled particles and their concentrations and compositions, the viral size particles, the epitopes, the concentrations of the fluorescent antibody stains and the non-associated concentrations of the fluorescent antibody stains can be or have any one or more of the characteristics described with respect to the fluid sample of the method aspects.

[0068] Other features of this and other aspects will be further understood with reference to the drawings and the discussion provided below, with reference to the embodiments described below, and with the claims. BRIEF DESCRIPTION OF THE DRAWINGS

[0070] Figure 1 A general flow diagram of some embodiments of the flow cytometry methods of the present invention is shown.

[0071] Figure 2 Shows Figure 1 A flowchart of some more specific process implementation plans in the general process.

[0072] Figure 3 shows that it can be used in flow cytometry with Figure 2 The processes shown are examples of processes performed together.

[0073] Figure 4 Shows Figure 1 A flowchart of some other more specific process implementation plans within the general process.

[0074] Figure 5 shows that it can be used in flow cytometry with Figure 4 The processes shown are examples of processes performed together.

[0075] Figure 6 Shows Figure 1 A flowchart of some other more specific process implementation plans within the general process.

[0076] Figure 7 shows that it can be used in flow cytometry with Figure 6 The processes shown are examples of processes performed together.

[0077] Figure 8 Shows Figure 1 A flowchart of some other more specific process implementation plans within the general process.

[0078] Fig. 9 Shows Figure 8 A flow chart of some more specific process implementation schemes in the crude sample purification step of the process.

[0079] Figure 10-11 is a graph summarizing the results of Example 1 given below.

[0080] Fig.12 is a graph summarizing the results of Example 2 given below.

[0081] Figure 13-14 is a graph summarizing the results of Example 3 given below.

[0082] Figure 15-16 is a graph summarizing the results of Example 4 given below.

[0083] Fig.17 is a graph summarizing the results of Example 5 given below.

[0084] Fig.18 is a graph summarizing the results of Example 6 given below.

[0085] Fig.19 is a graph summarizing the results of Example 7 given below.

[0086] Fig. 20 is a graph summarizing the results of Example 8 given below.

[0087] Fig.21 is a graph summarizing the results of Example 9 given below.

[0088] Figure 22-23 is a graph summarizing the results of Example 10 given below.

[0089] Figure 24-25 is a graph summarizing the results of Example 11 given below.

[0090] Fig.26 is a graph summarizing the results of Example 12 given below.

[0091] Figure 27-30 is a graph summarizing the results of Example 13 given below. DETAILED DESCRIPTION OF THE INVENTION

[0093] Figure 1A general flow chart diagram of a flow cytometric method for evaluating biological material for the presence of non-associated viral particles of a specific virus type of interest is shown. Figure 1 The method shown includes preparing a fluid sample 102 to prepare a fluid sample 104, and then subjecting the fluid sample 104 to flow cytometry 106. The fluid sample 104 resulting from the step of preparing the fluid sample 102 contains a fluorescent antibody stain capable of directly or indirectly binding to non-associated viral particles of a target viral type to form non-associated labeled particles that can be detected during the flow cytometry 106. Preparing the fluid sample 102 can include mixing a biological material to be tested with at least one fluorescent antibody stain. Figure 2 Shows Figure 1 A flow chart of a more specific exemplary embodiment of the general process shown, wherein preparing a fluid sample 102 includes a mixing 108 step, during which a biological material 110 to be evaluated is mixed with a fluorescent antibody stain 112, which is capable of binding directly or indirectly to an epitope indicating the target virus type being evaluated by the biological material 110. As introduced into the mixing 108, the biological material 110 can be present in a buffer solution at a concentration suitable for processing, and can be the result of a previous treatment of an initial crude sample from the biological material. Such a solution that can feed the biological material 110 into the mixing 108 can also contain other additives or reagents useful during the treatment. Similarly, the fluorescent antibody stain can be provided to the mixing 108 step together with one or more additives or other reagents in a properly buffered solution. For example, before mixing 108, the fluorescent antibody stain 112 can be provided in a buffer solution that also contains reagents for stabilizing, helping to protect or disperse the fluorescent antibody stain 112. For example, the fluorescent antibody stain 112 can be provided in a buffer solution containing an anti-aggregating agent (e.g., bovine albumin) and / or an antimicrobial agent (e.g., sodium azide). The buffer solution can be a phosphate buffer solution or other buffer solution at an appropriate pH.

[0094] Figure 3 It shows that it can be Figure 2 An example of a process performed during flow cytometry 106 according to an exemplary embodiment of the present invention. Figure 3 As shown, a fluid sample 104 flowing through a flow cell 114 of a flow cytometer is subjected to excitation radiation 116 in the flow cell 114, such as excitation radiation from a laser, LED, or other light source. Figure 3 In the example shown, the flow of the fluid sample 104 through the flow cell 114 is in the direction of flow arrow 118. The detector system 120 includes optical components for detecting radiation from the flow cell in the wavelength range of the fluorescent emission of the fluorescent antibody stain 112. Figure 3, the passage of non-associated labeled virus-sized particles 122 comprising virus particles having fluorescent antibody stains bound thereto is shown. Figure 3 Also shown is an example time plot 124 of the output of the photodetector (C1), which detects fluorescent emission and displays the peak voltage corresponding to the non-associated labeled particle 122 passing through the flow cell 114 at time t1. Also for illustration purposes, Figure 3 Residual, unbound fluorescent antibody stain 112 in the fluid sample 104 is shown, which causes some larger background peaks in the time plot 124 .

[0095] Flow cytometry was performed on 106 Figure 1 The fluid sample 104 may be made using two or more different fluorescent stains, at least one of which is a fluorescent antibody stain. Figure 4 Shown with Figure 2 The same example flow is shown, except that during the mixing 108 a second fluorescent stain 126 is provided to the mixing 108 step so that it is included in the fluid sample 104 undergoing flow cytometry 106. Figure 4 In the example shown, the second fluorescent stain 126 is a nucleic acid stain that is not selective for the virus type. The second fluorescent stain 126 can be a fluorescent stain and can be provided in a single formulation with the fluorescent antibody stain 112, or can be provided in a separate formulation. In the preferred process, the fluorescent antibody stain 112 and the second fluorescent stain 126 can be provided in a single formulation, such as a single buffer solution with a desired ratio to be included in the fluid sample 104. Figure 5 Shows Figure 4 An example of a flow cytometry 106 process. Figure 5 As shown, the flow of fluid sample 104 through flow cell 114 is subjected to excitation radiation 116 in flow cell 114. Figure 5 In the illustration shown, the detection system 120 includes a first photodetector for detecting fluorescent emissions from the fluorescent antibody stain 112 and a second photodetector for detecting different fluorescent emissions from a second fluorescent stain. Figure 5 An example of a non-associated labeled viral particle 128 comprising a fluorescent antibody stain 112 and a second fluorescent stain 126 attached thereto is shown. Figure 5A first time graph 130 is shown with an exemplary output (C1) of a first photodetector detecting fluorescent emission from a fluorescent antibody stain 112 and a second time graph 132 is shown with an exemplary output (C2) of a second photodetector detecting fluorescent emission from a second fluorescent stain 126. The temporal coincidence of the voltage peaks at time t2 in the first time graph 130 and the second time graph 132 indicates that non-associated labeled particles 128 passed through the flow cell 114. The voltage peaks at times t1 and t3 shown in the second time graph 132 indicate that particles containing the second fluorescent stain but not containing the fluorescent antibody stain 112 passed through the flow cell 114. Such particles that may contain the second fluorescent stain 126 but not the fluorescent antibody stain 112 may be, for example, viral particles of a different viral type than the viral type of the viral particles of the non-associated labeled particles 128. The larger background amplitude and larger background peak shown in the time graph 130 may indicate that unbound fluorescent antibody stain 112 passed through the flow cell 114. For purposes of illustration, Figure 5 The unbound fluorescent antibody stain 112 is shown to be present in the fluid sample 104 passing through the flow cell 114. The second time plot 132 includes a background pattern with a smaller background peak indicative of a second fluorescent stain, which is a fluorescent material that provides very little background fluorescence emission when not attached to nucleic acid on a particle.

[0096] Figure 6 Shown with Figure 4 The same example process as shown, except that the second fluorescent stain provided to the mixing step 108 is a second fluorescent antibody stain 134 that specifically binds to an epitope of a viral particle of a different virus type than the fluorescent antibody stain 112 (e.g., a different virus or a different serotype of the same virus). Figure 6 The illustrated process is used to differentiate between viral particles of different viral types present in the biological material 110 and to quantify the presence of viral particles of each of the two different types in the fluid sample. Figure 7 It shows that it can be Figure 6 The illustrated process example is an example of a process that occurs during flow cytometry 106 . Figure 7 and Figure 5 The same, except that a fluid sample 104 is shown which comprises an exemplary first type of non-associated labeled particles 136 comprising viral particles of a first virus type having a fluorescent antibody stain 112 attached thereto and a second type of non-associated labeled particles 138 comprising viral particles of a second virus type having a second antibody stain 134 attached thereto. Figure 7A first time graph 140 showing an exemplary output (C1) of a first photodetector detecting fluorescent emission from a fluorescent antibody stain 112 and a second time graph 142 showing an exemplary output (C2) of a second photodetector detecting fluorescent emission from a second antibody stain 134 are shown. For purposes of illustration, Figure 7 The fluid sample 104 in FIG. 1 is shown to contain a non-associated first fluorescent antibody stain 112 and a non-associated second fluorescent antibody stain 134. Figure 7 As shown, the voltage peak on the first time graph 140 at time t1 indicates that the first type of non-associated labeled particles 136 pass through the flow cell 114, and the voltage peak at t2 shown in the second time graph 142 indicates that the second type of non-associated labeled particles 138 pass through the flow cell 114.

[0097] Figure 8 Shown according to Figure 1 An example of a general process flow is shown, where preparing a fluid sample 102 includes a step 144 of purifying a crude sample prior to mixing 108. During purification of the crude sample 144, a crude sample 146 of biological material is subjected to a purification process to remove at least a portion of impurities that may interfere with flow cytometry 106 to prepare a more pure form of the biological material 110 for mixing with a fluorescent antibody stain 112 during mixing 108 to prepare the fluid sample 104. For purposes of illustration, Figure 8 The process in includes providing a second fluorescent stain 148 to the mixture 108 so that it is included in the fluid sample. The second fluorescent stain 148 can be a second fluorescent antibody stain different from the fluorescent antibody stain 112, or can be a non-specific fluorescent stain, such as a nucleic acid stain. The crude sample of biological material 146 can be provided in a diluted form with a buffer solution or other reagents, or it can be provided in an undiluted form, and can be treated or not treated before being introduced into the step of purifying the crude sample 144.

[0098] Fig. 9 Shows that you can Figure 8 An example of the process performed during the purification of the crude sample 144 step of the general process is shown. Fig. 9In the illustrated example flow, purification of crude sample 144 includes a chromatographic removal step 150 followed by a filtration step 152. During chromatographic removal 150, smaller sized impurities 154 are removed from the crude sample of biological material 146 by chromatography, wherein the smaller sized impurities 154 are retained in the chromatographic medium. The smaller sized impurities may be impurities smaller than the size of a virus. The treated liquid 156 from chromatographic removal 150 is then filtered 152 to filter out larger sized impurities 158. The larger sized impurities 158 may be removed as filter retentate, and the biological material 110 provided to mixing 108 may be or include the filtrate from filtration 152 or a portion thereof, with or without further processing. Example

[0099] In the following example, in Virus Flow cytometry test is carried out on 3100 flow cytometer (ViroCyt, Inc.). The figure of the relative dilution factor of the concentration of viral particles drawn in the figure mentioned in these embodiments is a logarithmic figure. The flow cytometry test using fluorescent antibody stain is carried out in the case of not washing the stained viral sample after dyeing and not detecting light scattering to assist particle detection. Except as otherwise noted below, the average number (F / P ratio) of the dye molecules (fluorophores) attached that the fluorescent antibody stain in these embodiments usually comprises is 3 to 7 relative to each antibody molecule in the fluorescent antibody stain. The fluorescent antibody stain concentration provided in these embodiments is the total concentration in the sample. It should be understood that some of these fluorescent antibody stains attach and dye the viral particles in the sample, but when the sample is carried out to flow cytometry, most of the fluorescent antibody stains in the sample will be in an unbound state usually. All sample fluids in these embodiments are prepared with buffer solutions with pH in the range of pH7 to pH8.

[0100] Examples 1-6

[0101] In Examples 1-6 below, the fluorescent antibody stains include an AcV1 monoclonal antibody specific for the gp64 envelope glycoprotein of baculovirus conjugated to the dye Alexa Fluor 532 (identified below and in the figures as AFAcV1 antibody stain) or conjugated to CF532 (identified below as CFAcV1 antibody stain).

[0102] Example 1

[0103] About 5x 10 6 Test preparations containing baculovirus and baculovirus-specific fluorescent antibody stain AFAcV1 were prepared at concentrations of 100 non-associated baculovirus particles / ml and different concentrations of fluorescent antibody stain. Flow cytometry was performed on the different test preparations. Fig.10 Summarized are the measured baseline voltage responses of a photodetector (photomultiplier tube) detecting the fluorescence emission of the AFAcV1 dye (including a baseline component resulting from unbound AFAcV1 dye remaining in solution) as a function of AFAcV1 concentration (μg / mL). Fig.11 The average peak height voltage of the specific fluorescence emission response of the identified detection events, which are indicative of baculovirus stained with AFAcV1 stain, is summarized as a function of the same AFAcV1 concentration (μg / mL). The AFAcV1 concentration shown is the total concentration in the test preparation, and therefore includes both AFAcV1 bound to baculovirus and unbound AFAcV1, however, most of the AFAcV1 in the test preparation will be in an unbound state, even if Fig.11 At the lowest total concentration shown.

[0104] like Fig.10 As shown, the nonspecific signal background in the test preparations increased with increasing concentration of AFAcV1 stain. Fig.11 As shown, the peak height of the voltage signal from the stained baculovirus increases at lower concentrations but reaches equilibrium as the baculovirus particles become saturated with AFAcV1 stain binding to the particles. Fig.10 and 11 As shown by comparison of , there is a narrow range of fluorescent antibody stain concentrations below about 8 μg / ml where the nonspecific voltage baseline is low enough and the specific voltage peak height of the stained baculovirus is high enough to enable the baculovirus stained by the fluorescent antibody stain to be discerned.

[0105] Embodiment 2:

[0106] Baculovirus test preparations were subjected to comparative flow cytometry testing, in which the fluorescent antibody stain AFAcV1 was used relative to conventional viruses stained with a combination of non-specific protein stains and non-specific nucleic acid stains (fluorescent stains). Conventional staining tests were performed using Combo Dye staining reagents (ViroCyt, Inc.), which were pre-formulated with appropriate ratios of non-specific protein stains and non-specific nucleic acid stains. Flow cytometry evaluation was performed on the test solutions. For the Combo Dye run, detection of baculovirus particles was counted only when there were independent and simultaneous detection events for fluorescence emission from the nucleic acid stain and the protein stain. For the fluorescent antibody stain, detection of baculovirus particles was counted based on detection events of fluorescence emission from AFAcV1 alone. For the AFAcV1 test, the total concentration of AFAcV1 stain (bound and unbound to baculovirus) in the test solution was approximately 3 μg / ml. For each of the Combo Dye and fluorescent antibody staining assays, four test solutions were prepared at different dilutions of the baculovirus stock solution to provide four different baculovirus concentrations, typically between 10 and 10 in buffer solution for each staining combination. 6 Up to 10 7 For specificity controls, fluorescent antibody stains were tested against an irrelevant virus, lentivirus, and a buffer solution without the presence of any virus type.

[0107] The results are summarized in Fig.12 In FIG. 1 , a graph showing the concentration of baculovirus determined by flow cytometry as a function of the dilution factor of the AFAcV1 staining assay in the ComboDye assay is shown. Both the vertical and horizontal axes are in logarithmic scale. Fig.12 As shown, the baculovirus concentration indicated for the AFAcV1 test is close to the concentration indicated by the Combo Dye test. Fig.12 It also summarizes the relative abundance of approximately log 5.5 particles per ml (approximately 1 x 10 5.5 The approximate lower limit of detection of the flow cytometer (particles / mL) was obtained using a flow cytometer with 100 μg / mL of lentivirus and blank medium. The results confirmed that the data from samples treated with the antibody stain were similar to those generated using Combo Dye. In addition, the antibodies were unable to bind to the lentivirus, confirming the specificity of the fluorescent antibody staining. In addition, the antibodies did not increase the background to unacceptable levels when added to blank medium.

[0108] Embodiment 3:

[0109] For containing about 1x 10 5 Up to 1x 10 8Flow cytometry dilution series were performed using various antibody stain concentrations, based on titrations of baculovirus solution at 100 baculovirus particles / mL. Each dilution series consisted of performing flow cytometry on 200 microliters of sample prepared at different dilutions of the baculovirus stock solution, wherein all samples in each dilution series contained the same concentration of fluorescent antibody stain. Four dilution series were performed at antibody stain concentrations of approximately 1.2, 2.5, 5, and 7.5 micrograms of CFAcV1 antibody stain per mL of sample. Flow cytometric testing was performed to detect and evaluate fluorescent emission from the stained baculovirus. The results of the flow cytometric testing for each dilution series are summarized in Fig.13 and 14 middle. Fig.13 A graph showing the uncorrected baculovirus concentration (viral particles / mL) of samples determined by flow cytometry testing is shown, while Fig.14 Shown are graphs of the same data, but corrected for the dilution factor. Both graphs are logarithmic. Fig.13 and 14 Good results (close to linear fit) were shown for intermediate dilution factors, with Fig.14 The dilution-corrected flow cytometry results shown are close to the actual baculovirus concentration of the baculovirus stock at the intermediate dilution factor. The results for lower dilution factors (higher baculovirus concentration in the sample) and higher dilution factors (lower baculovirus concentration in the sample) tend to be poor, which may indicate higher counts due to aggregation of some baculovirus particles at lower dilution factors and due to interference from background signal of unbound antibody stain at higher dilution factors.

[0110] Embodiment 4:

[0111] Comparative flow cytometry tests were performed using the fluorescent antibody stain CFAcV1 versus Combo Dye (a non-specific protein and nucleic acid fluorescent stain) similar to Example 1. The concentration of the fluorescent antibody stain in the sample was about 2.5 μg / mL. Fig.15 and 16 The results are summarized in Fig.15 The concentration of viral particles per milliliter determined by flow cytometry is plotted against the dilution factor. Fig.16 The same data corrected for the dilution factor are plotted, similar to the above for Fig.13 and 14 In this example, the virus concentration results produced using fluorescent antibody staining are always lower than those produced using Combo Dye, and as Fig.16 As shown, the dilution-corrected virus concentration results determined by flow cytometry using fluorescent antibody staining were closer to expectations based on the baculovirus concentration in the baculovirus stock.

[0112] Example 5 :

[0113] Baculovirus detection was assessed by flow cytometry using the fluorescent antibody stain FCAcV1 in the presence of fetal bovine serum (FBS). A titration of baculovirus containing approximately 1 x 10 7 Up to 1x 10 8 baculovirus particles / mL and about 3% FBS by volume (constant FBS), or diluted about 2.5 logs of FBS (reduced FBS). A flow cytometry dilution series was performed in which each sample contained about 2.5 μg / mL of fluorescent antibody stain. In one dilution series, additional FBS was added to the diluted samples so that the concentration of FBS in all flow cytometry samples in the dilution series was approximately the same as the stock solution (about 3% FBS by volume). In the second dilution series, no additional FBS was added, so the concentration of FBS was diluted along with the baculovirus concentration. The results of the two dilution series are shown in Figure 2. Fig.17 As summarized. Fig.17 As shown, the results of the two dilution series were very similar, indicating that the presence of FBS in the samples did not adversely affect baculovirus identification using fluorescent antibody staining.

[0114] Embodiment 6:

[0115] Perform a flow cytometry dilution series of a solution containing BacMam virus (modified baculovirus). Prepare a solution containing approximately 1 x 10 7 Up to 1x 10 8 The flow cytometry samples were prepared with a concentration of about 2.5 μg / ml of the fluorescent antibody stain CFAcV1. The results of the flow cytometry dilution series are shown in Figure 2. Fig.18 Shown is a graph which plots the concentration of BacMam virus per milliliter as determined by flow cytometry at different dilution factors and demonstrates a good linear fit to the data.

[0116] Embodiment 7-8

[0117] Adenovirus is a family of non-enveloped viruses (Adenoviridae) with a size of approximately 90 to 100 nanometers, which has an icosahedral nucleocapsid containing a double-stranded DNA genome of 26 to 48 kbp. Adenovirus is infectious to many vertebrate hosts, including many different serotypes that infect humans. Adenovirus is an important virus for many viral therapeutic applications, including oncolysis, gene therapy and immunotherapy applications. Adenovirus is one of the main means of delivering genetic payloads to specific cell types (especially tumor cells). Adenovirus has a high potential toxicity, and strict and accurate monitoring and quantification of adenovirus are very important at various manufacturing stages and for precise administration in viral therapeutic preparations. For example, it is known that adenovirus causes respiratory diseases in humans, mainly in children, and it is crucial that key viral genes are replaced by one or more therapeutic genes required. In order to avoid this problem, as well as the possibility of avoiding the host's immune response to the vector, non-human adenovirus strains are also being studied. One of the most problematic aspects of producing adenovirus viral vectors is the quantification of adenovirus viral vectors during growth, harvesting, purification and release.

[0118] In Examples 7 and 8 below, the fluorescent antibody stain is the 8C4 monoclonal antibody-CF 532 conjugate (hereinafter referred to as CF-8C4). The 8C4 antibody is specific for the hexon protein of adenovirus and is effective against different adenovirus serotypes (at least serotypes 2 to 6 were tested).

[0119] Embodiment 7:

[0120] Comparative flow cytometry of adenovirus test preparations was performed using the fluorescent antibody stain CF-8C4 on two different test preparations containing different adenovirus serotypes. One test preparation contained adenovirus serotype 4 and the other test preparation contained adenovirus serotype 5. For all tests, the total concentration of CF-8C4 antibody stain (bound and unbound to adenovirus) in the test solution was approximately 2.5 μg / mL. For each test preparation, four test solutions were prepared at different dilutions of the virus stock for each dilution series to provide four different virus concentrations for testing each test preparation in buffer solution.

[0121] The results are summarized in Fig.19 , which shows the adenovirus concentration at each dilution in a dilution series of each different serotype as a function of the dilution factor determined by flow cytometry. Both the vertical and horizontal axes are in logarithmic scale. Fig.19 As shown, the concentrations of each dilution series almost fell on the line indicating binding of CF-8C4 to both serotypes, but the data tended to fall below the detection limit of the flow cytometer (approximately 10 5.5particles / mL).

[0122] Embodiment 8:

[0123] Comparative flow cytometry testing was performed on adenovirus test preparations using the same fluorescent antibody stain as used in Example 1 (CF-8C4) relative to controls for influenza and lentivirus that were not antigenic to the 8C4 antibody. The adenovirus used in the test preparation was serotype 4. For all tests, the total concentration of CF-8C4 antibody stain (bound and unbound to adenovirus) in the test solution was approximately 2.5 μg / mL. For each dilution series, 6 test solutions were prepared at different dilutions of the adenovirus stock solution to provide 6 different virus concentrations for testing in buffer solution. For specific controls, the fluorescent antibody stain was tested against unrelated viruses of the influenza and lentivirus types.

[0124] The results are summarized in Fig. 20 , which shows the adenovirus concentration at each dilution as a function of the dilution factor of the different test preparations as determined by flow cytometry. Both the vertical and horizontal axes are in logarithmic scale. Fig. 20 As shown, for adenovirus, the concentration curve of the dilution series showed good linearity. Fig. 20 The approximate detection limit of the control preparation relative to the flow cytometer (approximately 10 5.5 The data of 100 μg / mL (particles / mL) showed that the fluorescent antibody stain failed to bind to influenza virus and lentivirus control, confirming the specificity of the fluorescent antibody stain.

[0125] Examples 9-10

[0126] Adeno-associated virus (AAV) is a family of small, non-enveloped viruses with a size of approximately 20 nanometers and a 4.7 kb single-stranded DNA genome. AAV has many serotypes that can infect dividing and quiescent cells in human hosts. AAV is an important virus for many virotherapy applications, including as a gene therapy vector. Due to its extremely small size, AAV is difficult to detect and accurately quantify, for example in manufacturing operations for preparing recombinant AAV and for drug administration control.

[0127] Adeno-associated virus (AAV) is generally non-replicating, and replication generally requires the presence of additional factors. For example, proteins of some adenoviral genes can be used to replicate AAV in the presence of adenovirus. Some advantages of using AAV as a viral vector are the absence of pathogenicity, low host immune response, and long-term expression. Accurate quantification of AAV during manufacturing and formulation operations is important for monitoring the performance of manufacturing constructs and tracking product yields as well as providing accurate dosages. Even if not pathogenic, overdosage of infectious viral agents such as adeno-associated viruses can also cause serious problems for patients.

[0128] One of the most problematic steps is quantification of AAV viral vectors during growth, harvesting, purification, and release. Methods such as quantitative PCR and absorbance readings at 260 nm and 280 nm are highly variable, leading to over- or under-estimation of particles at any given step. The consequences for manufacturing are product loss, delays, and cost overruns, which are serious but not as great as the risks associated with dosing too little (no therapeutic effect) or too much (adverse immune response) of a product. Clearly, there is a critical need for rapid, more accurate methods for quantification of AAV viral particles for vector-mediated gene therapy.

[0129] In the following Examples 9-10, flow cytometry testing of adeno-associated virus serotype 2 (AAV-2) was performed using a fluorescent antibody stain comprising anti-AAV-2 monoclonal antibody A20 (PROGEN Biotechnik) conjugated to Alexa Fluor 532 dye (hereinafter referred to as CF-A20 antibody stain). A20 is an antibody to a conformational epitope of the assembled capsid of AAV-2 and AAV-3.

[0130] Embodiment 9:

[0131] AAV-2 test preparations were subjected to comparative flow cytometry testing using fluorescent antibody stain CF-A20 relative to controls of AAV-5 and AAV-9 that were non-antigenic to the A20 antibody. Two different AAV-2 test preparations were prepared using AAV-2 obtained from different commercial sources. For all tests, the total concentration of CF-A20 antibody stain (bound and unbound to AAV-2) in the test solution was approximately 2.5 μg / ml. For each dilution series, five test solutions were prepared at different dilutions of the viral stock to provide five different virus concentrations for testing in buffer solution. For specific controls, fluorescent antibody stains were tested for AAV-5 and AAV-9 serotypes and buffer solutions containing CF-A20 but without any type of virus.

[0132] The results are summarized in Fig.21 , which shows the AAV-2 concentration of each AAV-2 sample determined by flow cytometry as a function of the dilution factor for the CF-A20 staining test and the control. Both the vertical and horizontal axes are logarithmic scales. Fig.21 As shown, the AAV-2 concentrations indicated by the CF-A20 test were similar for each of the two AAV-2 preparations tested. Fig.21 The approximate detection limit of the control preparation relative to the flow cytometer (approximately 10 5.5The data from the antibody stain treated AAV-2 samples were presented in Figure 2 (particles / mL). The results showed that the data from the antibody stain treated AAV-2 samples were fairly consistent between different sources of AAV-2. In addition, the antibodies failed to bind AAV-5 or AAV-9, confirming the specificity of the fluorescent antibody stain for AAV-2 relative to other serotypes. Furthermore, the fluorescent antibody stain did not increase the background to unacceptable levels when added to blank media.

[0133] Embodiment 10:

[0134] For containing about 1x 10 5 Up to 1x 10 8 Titration of AAV-2 solution at 100 AAV-2 particles / mL was performed using flow cytometry dilution series using various antibody stain concentrations. Each dilution series consisted of performing flow cytometry on 200 μL samples prepared at different dilutions of the AAV-2 stock solution, with all samples in each dilution series containing the same concentration of fluorescent antibody stain. Three dilution series were run with antibody stain concentrations of approximately 0.91, 1.82, and 2.73 μg CF-A20 antibody stain / mL of sample. Flow cytometry testing was performed to detect and evaluate the fluorescent emission of the stained AAV-2. The results of the flow cytometry testing for each dilution series are summarized in Fig. 22 and 23 middle. Fig. 22 A graph showing the uncorrected AAV-2 concentration (viral particles / mL) of samples determined by flow cytometry is shown. Fig.23 Graphs showing the same data, but corrected for the dilution factor. Both graphs are log-log graphs. Fig. 22 and 23 All showed generally good results (close to a linear fit) at intermediate dilution factors. Fig.23 The flow cytometry results shown, corrected for dilution, are close to the actual AAV-2 concentration of the AAV-2 stock at the intermediate dilution factors. The results trended down at lower dilution factors (higher AAV-2 concentration in the sample) and higher dilution factors (lower AAV-2 concentration in the sample), suggesting lower counts due to aggregation of some AAV-2 particles at lower dilution factors and higher counts due to possible interference from background signal from unbound antibody stain at higher dilution factors.

[0135] Examples 11-13

[0136] In Examples 11-13 below, various influenza virus types were tested by flow cytometry using a fluorescent antibody stain comprising the M149 polyclonal antibody (rabbit polyclonal antibody against human influenza A, B - Clontech / Takara) conjugated to CF532 dye (hereinafter referred to as M140-532 antibody stain).

[0137] Embodiment 11

[0138] Example M149-532 fluorescent antibody stain formulations were prepared at F / P ratios of 3, 5, and 7. Test formulations for flow cytometry testing were prepared to include influenza A virus particles / mL (rather than a titration of non-associated influenza virus) and flow cytometrically tested with each of the three formulations of M149-532 fluorescent antibody stain. Flow cytometry dilution series were run as follows: For each flow cytometry run, each of the different M149-532 formulations was used and the total concentration of each M149-532 fluorescent antibody stain was about 2.5 μg / mL. The results of the flow cytometry testing of the different dilution series are summarized in Fig.24 and 25 middle. Fig.24 Shows uncorrected viral particle counts per milliliter (not corrected for background signal), Fig.25 Displays the corrected viral particle count per milliliter (corrected for background signal). Fig.24 and Fig.25 As shown, the tests using F / P ratios of 5 and 7 showed good results (close to linearity) and consistent flow cytometry results across all dilution series, while the tests using F / P ratio of 3 showed consistent results for the highest viral particle concentration tested (dilution factor 10x), but not at the lower concentration points (dilution factors of 1000x and 10,000x) (where the viral particles measured per milliliter dropped significantly). It is noteworthy that even after correction for background, good and consistent results were obtained throughout the dilution series in the tests using F / P ratios of 5 and 7, but for the 10,000x dilution test using F / P ratio of 3, the labeled viral particle detection peak could not be distinguished from the background. The F / P ratio of 3 does not appear to be sufficient to fully conjugate with all antibodies in the antibody stain, so a large number of antibody molecules remain unconjugated to the fluorophore and can bind to viral particles but do not contribute to the fluorescence emission response of the labeled viral particles. In contrast, when using F / P ratios of 5 and 7, the fluorophore was conjugated to all or almost all of the antibody molecules, but no significant fluorescence emission quenching was caused due to the dense concentration of the fluorophore on the antibody molecules.

[0139] Example 12

[0140] Prepare test preparations containing influenza A virus or influenza B virus at a concentration of approximately 1 x 10 7 Non-associated viral particles / ml and containing different concentrations of M149-532 fluorescent antibody stain (1.25 μg / ml, 2.5 μg / ml and 3.75 μg / ml for influenza B test preparations and 1.25 μg / ml and 3.75 μg / ml for influenza A test preparations). Blank preparations containing corresponding concentrations of M149-532 (1.25 μg / ml, 2.5 μg / ml and 3.75 μg / ml) and no viral particles were also prepared. Flow cytometry was performed on the different test preparations and blank preparations. Fig.26 The measured average peak height voltage indicating the detection of fluorescently stained viral particles at different M149-532 concentrations in the test formulations and the background voltage peak of the blank formulation are summarized. Fig.26 As shown, the peak height of the voltage signal from the stained A and B influenza viruses increases with the increase of the concentration of the fluorescent antibody stain, as does the background peak value from the blank preparation. It is worth noting that the distance between the peak height voltage of the influenza B preparation and the corresponding blank voltage peak increases significantly between 1.25 μg / ml and 2.5 μg / ml of fluorescent antibody stain, but does not increase similarly from 2.5 μg / ml to 3.75 μg / ml. Testing higher concentrations of fluorescent antibody stains will begin to show that the distinction between the peak height voltage of the stained virus particles and the background voltage peak from the unbound fluorescent antibody stain is poor, due to the higher background voltage peaks caused by the unbound fluorescent antibody stain and dye aggregates from higher concentrations.

[0141] Embodiment 13

[0142] Test preparations were prepared for many different virus size particles of influenza virus types, including several serotypes of influenza A, influenza B, and some virus-like particles (including different hemagglutinin (H) subtypes). Some control preparations containing fluorescent antibody stains and adenovirus serotype 3 or adenovirus serotype 5 were also prepared. Flow cytometry was performed for the dilution series of each test preparation and each control preparation, wherein each dilution sample for flow cytometry contained a concentration of about 2.5 micrograms / ml of M149-532 fluorescent antibody stain. Table 4 summarizes the different virus size particles of the test preparations and control preparations.

[0143] Table 4

[0144]

[0145] The results are summarized in Figure 27-30 , which shows a graph of the measured particle concentration as a function of the dilution factor for all of these test formulations and the control formulation. Figure 27-30 As shown, all tested formulations containing influenza virus-type virus-sized particles showed good results (close to linear fit) throughout the dilution series, while the results of the adenovirus control formulation indicated the specificity of the M149-532 fluorescent antibody stain, which failed to bind to adenovirus particles.

[0146] Example Implementation Combinations

[0147] Some exemplary embodiment combinations and various types of implementation applications that may be the subject of the claims with or without the additional features disclosed above are disclosed below:

[0148] 1. A method for evaluating a sample of biological material for non-associated virus-sized particles having a specific epitope, the method comprising:

[0149] Performing flow cytometry on a fluid sample containing at least a portion of the biological material sample, wherein the fluid sample contains a fluorescent antibody stain that can directly or indirectly bind to a specific epitope, the flow cytometry comprising:

[0150] passing the fluid sample through a flow cell of a flow cytometer;

[0151] subjecting the fluid sample flowing through the flow cell to excitation radiation capable of inducing a fluorescent emission response from the fluorescent antibody stain; and

[0152] Radiation from the flow cell is detected within the wavelength range of the fluorescent emission and the detected radiation is evaluated to identify detection events indicative of passage of an unassociated labeled virus-sized particle comprising the virus-sized particle having the epitope and the fluorescent antibody stain through the flow cell.

[0153] For some VLP applications:

[0154] 2. The method according to example embodiment combination 1, wherein the biological material sample is suspected of containing virus-like particles.

[0155] 3. The method according to example embodiment combination 2, wherein the virus-sized particles are baculovirus particles of a different virus type than the virus-like particles, and the detection event indicates that a particle including a non-associated marker of the virus particle has passed through the flow cell. As a preferred embodiment, the fluorescent antibody stain may include an antibody for binding to the baculovirus gp64 envelope glycoprotein as an epitope, and optionally the antibody may be monoclonal (e.g., AcV1 monoclonal antibody).

[0156] 4. The method according to example embodiment combination 3, wherein:

[0157] The fluorescent antibody stain is a first fluorescent antibody stain, the epitope is a first epitope, the fluorescence emission is a first fluorescence emission, the detection is a first detection, the detection event is a first detection event, and the virus-like particle has a second epitope different from the first epitope;

[0158] The fluid sample comprises a second fluorescent antibody stain that is different from the first fluorescent antibody stain and is capable of directly or indirectly binding to a second epitope that is different from the first epitope, the second fluorescent antibody stain having a second fluorescent emission response to the excitation radiation that is different from the first fluorescent emission response; and

[0159] The flow cytometry comprises a second detection that detects second radiation originating from the flow cell within a wavelength range of a second fluorescent emission, and evaluates the detected second radiation to evaluate detection events indicative of a second non-associated labeled virus-sized particle passing through the flow cell, the second non-associated labeled virus-sized particle comprising the virus-like particle and a second fluorescent antibody stain.

[0160] 5. The method according to example embodiment combination 3 or example embodiment combination 4, wherein the second epitope is indicative of a virus type selected from the group consisting of: rhabdovirus, Nodamura virus, influenza virus, adenovirus, and adeno-associated virus.

[0161] 6. The method according to example embodiment combination 2, wherein the virus-sized particles are virus-like particles.

[0162] 7. The method according to example embodiment combination 6, wherein the virus-sized particles are of a virus type selected from the group consisting of: rhabdovirus, Nodamura virus, influenza virus, adenovirus, and adeno-associated virus.

[0163] 8. The method according to example embodiment combination 2, wherein the virus-sized particle is a virus particle of a different virus type than the virus-like particle, and the detection event is indicative of a particle comprising a non-associated marker of the virus particle passing through the flow cell.

[0164] 9. The method according to example embodiment combination 8, wherein:

[0165] The fluorescent antibody stain is a first fluorescent antibody stain, the epitope is a first epitope, the fluorescence emission is a first fluorescence emission, the detection is a first detection, the detection event is a first detection event, and the virus-like particle has a second epitope different from the first epitope;

[0166] The fluid sample comprises a second fluorescent antibody stain that is different from the first fluorescent antibody stain and is capable of directly or indirectly binding to a second epitope that is different from the first epitope, the second fluorescent antibody stain having a second fluorescent emission response to the excitation radiation that is different from the first fluorescent emission response; and

[0167] The flow cytometry comprises a second detection that detects second radiation originating from the flow cell within a wavelength range of a second fluorescent emission, and evaluates the detected second radiation to evaluate detection events indicative of a second non-associated labeled virus-sized particle passing through the flow cell, the second non-associated labeled virus-sized particle comprising the virus-like particle and a second fluorescent antibody stain.

[0168] 10. The method according to example embodiment combination 9, wherein the first epitope indicates a baculovirus type. Preferably, the first fluorescent antibody stain may include an antibody for binding to the baculovirus gp64 envelope glycoprotein as an epitope, and optionally the antibody may be monoclonal (e.g., AcV1 monoclonal antibody).

[0169] 11. The method according to example embodiment combination 8 or example embodiment combination 9, wherein the second epitope is indicative of a virus type selected from the group consisting of: rhabdovirus, Nodamivirus, influenza virus, adenovirus, and adeno-associated virus.

[0170] 12. The method according to any one of example embodiment combinations 2-11, wherein the epitope is a first epitope, the flow cytometry is a first flow cytometry, the fluid sample is a first fluid sample comprising the first portion of biological material sample, the non-associated labeled particles are first non-associated labeled particles and the excitation radiation is a first excitation radiation, and the method comprises:

[0171] Performing flow cytometry on a second fluid sample comprising a second portion of the biological material sample, wherein the fluid sample comprises a second fluorescent antibody stain that is different from the first antibody stain and is capable of directly or indirectly binding to a second epitope that is different from the first epitope, the second flow cytometry comprising:

[0172] passing a second fluid sample through a flow cell of a flow cytometer;

[0173] subjecting a second fluid sample flowing through the flow cell to a second excitation radiation that is the same as or different from the first excitation radiation and that is capable of inducing a second fluorescent emission response from the second fluorescent antibody stain that is different from the first fluorescent emission response; and

[0174] Radiation from the flow cell is detected within the wavelength range of the fluorescent emission and the detected radiation is evaluated to identify detection events indicative of a second non-associated labeled virus size particle passing through the flow cell, the second non-associated labeled virus size particle comprising a virus size particle having a second epitope and a second fluorescent antibody stain.

[0175] 13. The method according to example embodiment combination 12, wherein:

[0176] The first and second fluid samples each contain at least two different fluorescent antibody stains to directly or indirectly bind to two different epitopes; and

[0177] The first and second fluid samples each contain at least one fluorescent antibody stain that is not present in the other fluid sample.

[0178] 14. A method according to example embodiment combination 13, wherein at least two fluorescent antibody stains of each of the fluid samples target detection of at least two different types of virus-sized particles in the fluid samples, and at least one of the types of particles is different between the first sample fluid and the second sample fluid.

[0179] 15. The method according to any one of example embodiment combinations 2-14, wherein the biological material sample is a sample collected from a stage of a production operation for producing virus-like particles, during which the virus-like particles are expected to be present in the biological material.

[0180] 16. A method for preparing a product comprising virus-like particles, the method comprising:

[0181] A production process is used to prepare a purified product containing virus-like particles, the production process comprising:

[0182] Generation of virus-like particles during bioproduction operations;

[0183] harvesting a crude product from the bioproduction operation, which comprises virus-like particles produced during the production process;

[0184] purifying at least a portion of the crude product material to produce a purified product comprising virus-like particles;

[0185] collecting a sample of biological material from a stage of the production process during which virus-like particles are expected to be present in the biological material;

[0186] The sample is evaluated for the presence of virus-sized particles having a specific epitope, the evaluation comprising performing a method according to any one of example embodiment combinations 2-15.

[0187] 17. The method according to example embodiment combination 16, comprising performing said collecting a plurality of times to collect different said biological material samples to be evaluated from a plurality of different said stages and performing said evaluation on each of said collected biological material samples to be evaluated.

[0188] 18. The method according to example embodiment combination 17, wherein a plurality of different said stages comprises at least a first stage during said production or harvesting and a second stage during or after said purification.

[0189] For some flu apps:

[0190] 19. The method according to example embodiment combination 1, wherein the biological material sample is suspected of containing influenza virus particles.

[0191] 20. The method according to example embodiment combination 19, wherein the virus-sized particles are influenza virus particles.

[0192] 21. The method according to example embodiment combination 20, wherein:

[0193] The fluorescent antibody stain is a first fluorescent stain, the fluorescent emission is a first fluorescent emission, the detection is a first detection and the detection event is a first detection event;

[0194] The fluid sample comprises a second fluorescent stain for nucleic acids, the second fluorescent stain having a second fluorescent emission response to the excitation radiation when attached to the nucleic acids, the second fluorescent emission response being different from the first fluorescent emission response; and

[0195] The flow cytometry comprises a second detection that detects second radiation originating from the flow cell within a wavelength range of a second fluorescent emission and evaluates the detected second radiation to evaluate for detection events indicative of passage of virus-sized particles comprising nucleic acid stained with a second fluorescent stain; and

[0196] The results of the first detection and the second detection are compared to identify whether the first detection event and the second detection event occur in time coincident with each other, which further indicates that the non-associated labeled particles comprising the influenza virus particles have passed through the flow cell.

[0197] 22. The method according to example embodiment combination 20, wherein:

[0198] The fluorescent antibody stain is a first fluorescent antibody stain, the epitope is a first epitope, the fluorescence emission is a first fluorescence emission, the detection is a first detection and the detection event is a first detection event;

[0199] The fluid sample comprises a second fluorescent antibody stain that is different from the first fluorescent antibody stain and is capable of directly or indirectly binding to a second epitope that is different from the first epitope, the second fluorescent antibody stain having a second fluorescent emission response to the excitation radiation that is different from the first fluorescent emission response; and

[0200] The flow cytometry includes a second detection that detects second radiation originating from the flow cell within a wavelength range of a second fluorescent emission, and evaluates the detected second radiation to evaluate detection events indicative of non-associated labeled virus-sized particles passing through the flow cell, the non-associated labeled virus-sized particles comprising a virus-sized particle having a second epitope and a second fluorescent antibody stain.

[0201] 23. The method according to example embodiment combination 22, wherein said first epitope and second epitope are indicative of influenza virus.

[0202] 24. The method according to example embodiment combination 22, wherein the second epitope is indicative of a different influenza virus serotype than the first epitope.

[0203] 25. The method according to any one of example embodiment combination 22-24, wherein the first epitope is indicative of the presence of an influenza hemagglutinin antigen and the second epitope is indicative of the presence of an influenza neuraminidase antigen.

[0204] 26. The method according to any one of example embodiment combination 22-24, wherein the first epitope indicates the presence of a first influenza hemagglutinin antigen and the second epitope indicates the presence of a second influenza hemagglutinin antigen different from the first influenza hemagglutinin antigen.

[0205] 27. The method according to any one of example embodiment combination 22-24, wherein the first epitope indicates the presence of a first influenza neuraminidase antigen and the second epitope indicates the presence of a second influenza neuraminidase antigen different from the first influenza neuraminidase antigen.

[0206] 28. The method according to any one of example embodiment combination 22-27, wherein the influenza virus is an influenza A virus or an influenza B virus.

[0207] 29. The method according to any one of example embodiment combinations 20-28, wherein the epitope is a first epitope, the flow cytometry is a first flow cytometry, the fluid sample is a first fluid sample comprising the first portion of biological material sample, the non-associated labeled particles are first non-associated labeled particles and the excitation radiation is a first excitation radiation, and the method comprises:

[0208] Performing flow cytometry on a second fluid sample comprising a second portion of the biological material sample, wherein the fluid sample comprises a second fluorescent antibody stain that is different from the first antibody stain and is capable of directly or indirectly binding to a second epitope that is different from the first epitope, the second flow cytometry comprising:

[0209] passing a second fluid sample through a flow cell of a flow cytometer;

[0210] subjecting a second fluid sample flowing through the flow cell to a second excitation radiation that is the same as or different from the first excitation radiation and that is capable of inducing a second fluorescent emission response from the second fluorescent antibody stain that is different from the first fluorescent emission response; and

[0211] Radiation from the flow cell is detected within the wavelength range of the fluorescent emission and the detected radiation is evaluated to identify detection events indicative of passage of a second non-associated labeled virus-sized particle comprising a virus-sized particle having a second epitope and a second fluorescent antibody stain through the flow cell.

[0212] 30. The method according to example embodiment combination 29, wherein:

[0213] The first and second fluid samples each contain at least two different fluorescent antibody stains to directly or indirectly bind to two different epitopes; and

[0214] The first and second fluid samples each contain at least one fluorescent antibody stain that is not present in the other fluid sample.

[0215] 31. A method according to example embodiment combination 30, wherein at least two fluorescent antibody stains of each of the fluid samples target detection of at least two different types of virus-sized particles in the fluid samples, and at least one of the types of particles is different between the first sample fluid and the second sample fluid.

[0216] 32. The method according to example embodiment combination 31, wherein at least one fluorescent antibody stain in the first fluid sample targets the detection of an epitope of a first influenza virus serotype, and at least one fluorescent antibody stain in the second fluid sample targets the detection of an epitope of a second influenza virus serotype different from the first influenza virus serotype.

[0217] 33. The method according to any one of example embodiment combination 20-32, wherein the sample of biological material is a sample collected from a stage of a production operation in which influenza virus particles are produced, during which stage influenza virus particles are expected to be present in the biological material.

[0218] 34. A method for preparing a product comprising influenza virus particles, the method comprising:

[0219] A production process to prepare a purified product containing influenza virus particles, the production process comprising:

[0220] Generation of influenza virus particles in bioproduction operations;

[0221] harvesting from the bioproduction operation a crude product comprising influenza virus particles produced during the production process;

[0222] purifying at least a portion of the crude product material to produce a purified product comprising influenza virus particles;

[0223] collecting samples of biological material from a stage of the production process during which influenza virus particles are expected to be present in the biological material;

[0224] The sample is evaluated for the presence of virus-sized particles having a specific epitope, the evaluation comprising performing a method according to any one of example embodiment combinations 19-34.

[0225] 35. The method according to example embodiment combination 34, comprising performing said collecting a plurality of times to collect different said biological material samples to be evaluated from a plurality of different said stages, and performing said evaluation on each of said collected biological material samples to be evaluated.

[0226] 36. The method according to example embodiment combination 35, wherein said plurality of different said stages comprises at least a first stage during said production or harvesting and a second stage during or after said purification.

[0227] For some baculovirus applications:

[0228] 37. The method according to example embodiment combination 1, wherein the biological material sample is suspected of containing baculovirus particles.

[0229] 38. The method according to example embodiment combination 37, wherein the virus-sized particles are baculovirus particles. As a preference, the fluorescent antibody stain may include an antibody for binding to the baculovirus gp64 envelope glycoprotein as an epitope, and optionally the antibody may be monoclonal (e.g., AcV1 monoclonal antibody).

[0230] 39. The method according to example embodiment combination 38, wherein:

[0231] The fluorescent antibody stain is a first fluorescent stain, the fluorescent emission is a first fluorescent emission, the detection is a first detection and the detection event is a first detection event;

[0232] The fluid sample comprises a second fluorescent stain for nucleic acids, the second fluorescent stain having a second fluorescent emission response to the excitation radiation when attached to the nucleic acids, the second fluorescent emission response being different from the first fluorescent emission response; and

[0233] The flow cytometry comprises a second detection that detects second radiation originating from the flow cell within a wavelength range of a second fluorescent emission and evaluates the detected second radiation to evaluate for detection events indicative of passage of virus-sized particles comprising nucleic acid stained with a second fluorescent stain; and

[0234] The results of the first detection and the second detection are compared to identify whether the first detection event and the second detection event occur coincident in time, which further indicates that the non-associated labeled particles comprising the baculovirus particles have passed through the flow cell.

[0235] 40. The method according to example embodiment combination 38, wherein:

[0236] The fluorescent antibody stain is a first fluorescent antibody stain, the epitope is a first epitope, the fluorescence emission is a first fluorescence emission, the detection is a first detection and the detection event is a first detection event;

[0237] The fluid sample comprises a second fluorescent antibody stain that is different from the first fluorescent antibody stain and is capable of directly or indirectly binding to a second epitope that is different from the first epitope, the second fluorescent antibody stain having a second fluorescent emission response to the excitation radiation that is different from the first fluorescent emission response; and

[0238] The flow cytometry includes a second detection that detects second radiation originating from the flow cell within a wavelength range of a second fluorescent emission, and evaluates the detected second radiation to evaluate detection events indicative of non-associated labeled virus-sized particles passing through the flow cell, the non-associated labeled virus-sized particles comprising a virus-sized particle having a second epitope and a second fluorescent antibody stain.

[0239] 41. The method according to example embodiment combination 40, wherein the first epitope is indicative of a baculovirus and the second epitope is indicative of a second virus type different from a baculovirus.

[0240] 42. The method according to example embodiment combination 41, wherein the second virus type is selected from the group consisting of rhabdovirus, Nodamura virus, influenza virus, adenovirus, and adeno-associated virus.

[0241] 43. The method according to any one of example embodiment combinations 38-42, wherein the epitope is a first epitope, the flow cytometry is a first flow cytometry, the fluid sample is a first fluid sample comprising the first portion of biological material sample, the non-associated labeled particles are first non-associated labeled particles and the excitation radiation is a first excitation radiation, and the method comprises:

[0242] Performing flow cytometry on a second fluid sample comprising a second portion of the biological material sample, wherein the fluid sample comprises a second fluorescent antibody stain that is different from the first antibody stain and is capable of directly or indirectly binding to a second epitope that is different from the first epitope, the second flow cytometry comprising:

[0243] passing a second fluid sample through a flow cell of a flow cytometer;

[0244] subjecting a second fluid sample flowing through the flow cell to a second excitation radiation that is the same as or different from the first excitation radiation and that is capable of inducing a second fluorescent emission response from the second fluorescent antibody stain that is different from the first fluorescent emission response; and

[0245] Radiation from the flow cell is detected within the wavelength range of the fluorescent emission and the detected radiation is evaluated to identify detection events indicative of passage of a second non-associated labeled virus-sized particle comprising a virus-sized particle having a second epitope and a second fluorescent antibody stain through the flow cell.

[0246] 44. The method according to example embodiment combination 43, wherein:

[0247] The first and second fluid samples each contain at least two different fluorescent antibody stains to directly or indirectly bind to two different epitopes; and

[0248] The first and second fluid samples each contain at least one fluorescent antibody stain that is not present in the other fluid sample.

[0249] 45. A method according to example embodiment combination 44, wherein at least two fluorescent antibody stains of each of the fluid samples target detection of at least two different types of virus-sized particles in the fluid samples, and at least one of the types of particles is different between the first sample fluid and the second sample fluid.

[0250] 46. ​​The method according to example embodiment combination 45, wherein at least one fluorescent antibody stain in the first fluid sample targets detection of an epitope of a baculovirus and at least one fluorescent antibody stain in the second fluid sample targets detection of an epitope of a second virus type other than a baculovirus.

[0251] 47. The method according to any one of example embodiment combinations 38-46, wherein the sample of biological material is a sample collected from a stage of a production operation for producing baculovirus particles, during which stage baculovirus particles are expected to be present in the biological material.

[0252] 48. A method for preparing a product comprising baculovirus particles, the method comprising:

[0253] A production process to prepare a purified product comprising baculovirus particles, the production process comprising:

[0254] Generation of baculovirus particles in bioproduction operations;

[0255] harvesting from the bioproduction operation a crude product comprising baculovirus particles produced during the production process;

[0256] purifying at least a portion of the crude product material to produce a purified product comprising baculovirus particles;

[0257] collecting a sample of biological material from a stage of the production process during which baculovirus particles are expected to be present in the biological material;

[0258] The sample is evaluated for the presence of virus-sized particles having a specific epitope, the evaluation comprising performing a method according to any one of example embodiment combinations 37-47.

[0259] 49. The method according to example embodiment combination 48, comprising performing said collecting a plurality of times to collect different said biological material samples to be evaluated from a plurality of different said stages and performing said evaluation on each of said collected biological material samples to be evaluated.

[0260] 50. The method according to example embodiment combination 49, wherein said plurality of different said stages comprises at least a first stage during said production or harvesting and a second stage during or after said purification.

[0261] 51. The method according to any one of example embodiment combination 48-49, wherein the baculovirus has been modified to express a recombinant protein, and the method comprises producing and recovering the recombinant protein.

[0262] For some virus applications:

[0263] 52. A method according to example embodiment combination 1, wherein the biological material sample is suspected of containing viral particles of a viral type.

[0264] 53. The method according to example embodiment combination 52, wherein said virus-sized particles are virus-type virus particles.

[0265] 54. The method according to example embodiment combination 53, wherein:

[0266] The fluorescent antibody stain is a first fluorescent stain, the fluorescent emission is a first fluorescent emission, the detection is a first detection and the detection event is a first detection event;

[0267] The fluid sample comprises a second fluorescent stain for nucleic acids, the second fluorescent stain having a second fluorescent emission response to the excitation radiation when attached to the nucleic acids, the second fluorescent emission response being different from the first fluorescent emission response; and

[0268] The flow cytometry comprises a second detection that detects second radiation originating from the flow cell within a wavelength range of a second fluorescent emission and evaluates the detected second radiation to evaluate for detection events indicative of passage of virus-sized particles comprising nucleic acid stained with a second fluorescent stain; and

[0269] The results of the first detection and the second detection are compared to identify whether the first detection event and the second detection event occur coincident in time, which further indicates that the non-associated labeled particles including the viral particles pass through the flow cell.

[0270] 55. The method according to example embodiment combination 53, wherein:

[0271] The fluorescent antibody stain is a first fluorescent antibody stain, the epitope is a first epitope, the fluorescence emission is a first fluorescence emission, the detection is a first detection and the detection event is a first detection event;

[0272] The fluid sample comprises a second fluorescent antibody stain that is different from the first fluorescent antibody stain and is capable of directly or indirectly binding to a second epitope that is different from the first epitope, the second fluorescent antibody stain having a second fluorescent emission response to the excitation radiation that is different from the first fluorescent emission response; and

[0273] The flow cytometry includes a second detection that detects second radiation originating from the flow cell within a wavelength range of a second fluorescent emission, and evaluates the detected second radiation to evaluate detection events indicative of non-associated labeled virus-sized particles passing through the flow cell, the non-associated labeled virus-sized particles comprising a virus-sized particle having a second epitope and a second fluorescent antibody stain.

[0274] 56. The method according to example embodiment combination 55, wherein the first epitope is indicative of a first virus type and the second epitope is indicative of a second virus type different from the first virus type.

[0275] 57. The method according to example embodiment combination 56, wherein the first virus type is a baculovirus. Preferably, the first fluorescent antibody stain may include an antibody for binding to the baculovirus gp64 envelope glycoprotein as an epitope, and optionally the antibody may be monoclonal (e.g., AcV1 monoclonal antibody).

[0276] 58. The method according to example embodiment combination 56 or example embodiment combination 57, wherein the second virus type is selected from the group consisting of rhabdovirus, Nodamura virus, influenza virus, adenovirus, and adeno-associated virus.

[0277] 59. The method according to any one of example embodiment combinations 53-58, wherein the epitope is a first epitope, the flow cytometry is a first flow cytometry, the fluid sample is a first fluid sample comprising the first portion of biological material sample, the non-associated labeled particles are first non-associated labeled particles and the excitation radiation is a first excitation radiation, and the method comprises:

[0278] Performing flow cytometry on a second fluid sample comprising a second portion of the biological material sample, wherein the fluid sample comprises a second fluorescent antibody stain that is different from the first antibody stain and is capable of directly or indirectly binding to a second epitope that is different from the first epitope, the second flow cytometry comprising:

[0279] passing a second fluid sample through a flow cell of a flow cytometer;

[0280] subjecting a second fluid sample flowing through the flow cell to a second excitation radiation that is the same as or different from the first excitation radiation and that is capable of inducing a second fluorescent emission response from the second fluorescent antibody stain that is different from the first fluorescent emission response; and

[0281] Radiation from the flow cell is detected within the wavelength range of the fluorescent emission and the detected radiation is evaluated to identify detection events indicative of passage of a second non-associated labeled virus-sized particle comprising a virus-sized particle having a second epitope and a second fluorescent antibody stain through the flow cell.

[0282] 60. The method according to example embodiment combination 59, wherein:

[0283] The first and second fluid samples each include at least two different fluorescent antibody stains to directly or indirectly bind to two different epitopes; and

[0284] The first and second fluid samples each contain at least one fluorescent antibody stain that is not present in the other fluid sample.

[0285] 61. A method according to example embodiment combination 60, wherein at least two fluorescent antibody stains of each of the fluid samples target detection of at least two different types of virus-sized particles in the fluid samples, and at least one of the types of particles is different between the first sample fluid and the second sample fluid.

[0286] 62. A method according to example embodiment combination 61, wherein at least one fluorescent antibody stain in the first fluid sample targets the detection of an epitope of a first virus type and at least one fluorescent antibody stain in the second fluid sample targets the detection of an epitope of a second virus type different from the first virus type.

[0287] 63. A method according to any one of example embodiment combinations 53-62, wherein the sample of biological material is a sample collected from a stage of a production operation for producing viral particles, during which stage viral particles are expected to be present in the biological material.

[0288] 64. A method for preparing a product comprising viral particles, the method comprising:

[0289] A production process to prepare a purified product containing the virus particles, the production process comprising:

[0290] Generation of viral particles in bioproduction operations;

[0291] harvesting from the bioproduction operation a crude product comprising viral particles produced during the production process;

[0292] purifying at least a portion of the crude product material to produce a purified product comprising the viral particles;

[0293] collecting samples of biological material from a stage of the production process during which viral particles are expected to be present in the biological material;

[0294] The sample is evaluated for the presence of virus-sized particles having a specific epitope, the evaluation comprising performing a method according to any one of example embodiment combinations 52-63.

[0295] 65. The method according to example embodiment combination 64, comprising performing said collecting a plurality of times to collect different said biological material samples to be evaluated from a plurality of different said stages, and performing said evaluation on each of said collected biological material samples to be evaluated.

[0296] 66. The method according to example embodiment combination 65, wherein a plurality of different said stages comprises at least a first stage during said production or harvesting and a second stage during or after said purification.

[0297] For some nanoparticle applications:

[0298] 67. The method according to example embodiment combination 1, wherein the virus-sized particle is a nanoparticle, which is an exosome or is not an exosome.

[0299] Some other example implementation combinations:

[0300] 68. A method according to any one of example embodiment combinations 1-67, wherein the biological material in the fluid sample is a purified biological material, wherein larger size components are removed, the filter size is no greater than 2 microns, and the concentration of the fluorescent antibody stain that is not bound to non-associated labeled particles contained in the fluid sample ranges from 0.25 micrograms / milliliter of the fluid sample to 10 micrograms / milliliter of the fluid sample.

[0301] 69. The method according to any one of example embodiment combinations 1-68, wherein the fluid sample injected into the flow cytometer comprises a total concentration of fluorescent antibody stain in the range of 0.25 μg / mL to 10 μg / mL.

[0302] 70. The method according to any of example embodiment combinations 1-69, wherein said non-associated labeled particles have a maximum cross-sectional dimension ranging from 10 nanometers to 2 micrometers.

[0303] 71. The method according to any of example embodiment combination 1-70, wherein the excitation radiation comprises radiation in the wavelength range of 520 nanometers to 550 nanometers.

[0304] 72. The method according to any of example embodiment combination 1-71, wherein the fluorescent emission has a wavelength with a Stokes shift of at least 10 nanometers.

[0305] 73. A method according to any of example embodiment combinations 1-72, wherein the fluid sample injected into the flow cytometer contains a concentration of fluorescent antibody stain that is not bound to non-associated labeled particles in the range of 0.25 μg / mL to 10 μg / mL.

[0306] 74. The method according to any one of example embodiment combinations 1-73, wherein the fluid sample injected into the flow cytometer has a concentration of non-associated labeled particles in the range of 1 x 10 5 Up to 1x 10 9 Particles / ml.

[0307] 75. The method according to any one of example embodiment combination 1-74, wherein said fluorescent antibody stain comprises a fluorophore attached to an antibody molecule.

[0308] 76. The method according to example embodiment combination 75, wherein the fluorescent antibody stain comprises an average of 3 to 8 attached fluorophores per antibody molecule.

[0309] 77. The method according to example embodiment combination 75 or example embodiment combination 76, wherein said antibody molecule is monoclonal.

[0310] 78. The method according to example embodiment combination 75 or example embodiment combination 76, wherein said antibody molecule is polyclonal.

[0311] 79. The method according to any one of example embodiment combinations 1-78, wherein said flow cytometry comprises flowing said fluid sample through a flow cell at a fluid sample flow rate in the range of 250 to 3000 nanoliters per minute.

[0312] 80. The method according to any one of example embodiment combinations 1-79, comprising:

[0313] The fluid sample is prepared by mixing the biological material to be assessed for the presence of non-associated particles with a fluorescent antibody stain that binds directly or indirectly to an epitope to form non-associated labeled virus-sized particles.

[0314] 81. A method according to example embodiment combination 80, wherein the preparing the fluid sample includes, before mixing, purifying a crude sample of biological material to prepare the biological material for the fluid sample for flow cytometry, the purification including filtering out particles of the crude sample at a filter size not greater than 2 microns and chromatographically removing at least a portion of impurities smaller than the size of a virus.

[0315] 82. The method according to example embodiment combination 81, wherein said chromatographic removal comprises spinning the chromatograms in a centrifuge.

[0316] 83. A method according to any of example embodiment combinations 80-82, wherein said preparing the fluid sample comprises, after mixing, not removing fluorescent antibodies not bound to non-associated labeled particles from the fluid sample prior to flow cytometry.

[0317] 84. The method according to any one of example embodiment combination 1-84, wherein said fluorescent antibody stain comprises a biotinylated antibody and a fluorophore-conjugated streptavidin.

[0318] 85. The method according to example embodiment combination 84, wherein said fluorophore-conjugated streptavidin is attached to the biotinylated antibody when provided for mixing as mentioned in any one of example embodiments combination 80-83.

[0319] 86. The method according to example embodiment combination 85, wherein the fluorophore-conjugated streptavidin and biotinylated antibody are provided in separate formulations for mixing, and the fluorophore-conjugated streptavidin attaches to the biotinylated antibody in solution during mixing.

[0320] 87. The method according to any of example embodiment combination 1-86, wherein the flow cytometry does not detect light scatter.

[0321] 88. The method according to any of example embodiment combinations 1-87, wherein the fluid sample injected into the flow cytometer comprises a total concentration of fluorescent antibody stain in the range of 0.5 μg / mL to 10 μg / mL.

[0322] 89. A method according to any of example embodiment combinations 1-88, wherein the fluid sample injected into the flow cytometer contains a concentration of fluorescent antibody stain that is not bound to non-associated labeled particles in the range of 0.5 μg / mL to 10 μg / mL.

[0323] 90. A method according to any one of example embodiment combinations 1-89, wherein the fluorescent antibody stain is a first fluorescent stain and the fluid sample contains a second fluorescent stain having a second fluorescent emission response caused by excitation radiation, the second fluorescent emission response being different from the first fluorescent emission response of the first fluorescent stain.

[0324] 91. The method of example embodiment combination 90, wherein the second fluorescent stain comprises a fluorescent nucleic acid stain that is not specific to the particle type.

[0325] 92. The method according to example embodiment combination 90, wherein:

[0326] The non-associated particle is a first non-associated particle, the epitope is a first epitope, the non-associated particle is a first particle type and the non-associated labeled particle is a first non-associated labeled particle;

[0327] The second fluorescent stain is a second fluorescent antibody stain different from the first fluorescent antibody stain and the second fluorescent antibody stain is capable of binding to a second non-associated virus-sized particle having a second epitope indicative of a second particle type different from the first particle type to form a second non-associated labeled virus-sized particle; and

[0328] The method includes detecting radiation from the flow cell within the wavelength range of a second fluorescent emission and evaluating the detected radiation to identify detection events indicative of passage of a particle having a second unassociated label through the flow cell.

[0329] 93. The method according to any of example embodiment combination 90-92, wherein the second fluorescent emission has a peak wavelength that is at least 20 nanometers different from the peak wavelength of the first fluorescent emission.

[0330] 94. A method according to any one of example embodiment combinations 1-93, wherein each said fluorescent antibody stain is capable of directly binding to a corresponding said non-associated particle to form a corresponding said non-associated labeled particle.

[0331] 95. The method according to any of example embodiment combinations 1-94, wherein the flow cytometry comprises passing a fluid sample stream through hydrodynamic focusing with a sheath fluid, and passing the fluid sample and sheath fluid through a flow cell.

[0332] 96. The method according to any one of example embodiment combinations 1-95, wherein the flow cytometry comprises independent detection of at least two different fluorescent emissions and no detection of light scatter.

[0333] 97. The method according to any one of example embodiment combination 1-96, wherein said non-associated labeled particles are viral particles of a viral type.

[0334] 98. The method according to example embodiment combination 97, wherein the virus particle comprises a member selected from the group consisting of a virus-type virus particle, a virus-type virus-like particle, and a combination thereof.

[0335] 99. The method according to example embodiment combination 97 or example embodiment combination 9, wherein the virus type is a baculovirus type.

[0336] 100. The method of example embodiment combination 97 or example embodiment combination 98, wherein the virus type is an adenovirus type.

[0337] 101. The method of example embodiment combination 97 or example embodiment combination 98, wherein the virus type is an adeno-associated virus type.

[0338] 102. The method of example embodiment combination 97 or example embodiment combination 98, wherein the virus type is an influenza virus type.

[0339] 103. The method according to any of example embodiment combination 1-102, wherein the non-associated viral particles have a maximum cross-sectional dimension ranging from 10 nanometers to 2 micrometers.

[0340] 104. A method according to any one of example embodiment combinations 1-103, wherein the fluorescent antibody stain is a first fluorescent stain and the fluid sample contains a second fluorescent stain having a second fluorescent emission response caused by excitation radiation, and the second fluorescent emission response is different from the first fluorescent emission response of the first fluorescent stain.

[0341] 105. The method according to example embodiment combination 104, wherein the second fluorescent stain comprises a fluorescent nucleic acid stain that is not specific to the particle type.

[0342] 106. The method according to example embodiment combination 104, wherein:

[0343] the non-associated labeled particle is a first non-associated labeled particle, the epitope is a first epitope, the viral size particle is a first viral size particle, the viral type is a first viral type and the non-associated labeled particle is a first non-associated labeled particle;

[0344] The second fluorescent stain is a second fluorescent antibody stain different from the first fluorescent antibody stain and the second fluorescent antibody stain is capable of binding to a second virus size particle having a second epitope indicative of a second virus type different from the first virus type to form a second non-associated labeled virus size particle; and

[0345] The method includes detecting radiation from the flow cell within the wavelength range of a second fluorescent emission and evaluating the detected radiation to identify detection events indicative of passage of a second non-associated labeled particle through the flow cell.

[0346] 107. A method according to example embodiment combination 106, wherein the second fluorescent emission has a peak wavelength that is at least 20 nanometers different from the peak wavelength of the first fluorescent emission, and the flow cytometry includes independently detecting at least the first and second fluorescent emissions and not detecting light scattering.

[0347] 108. The method according to example embodiment combination 107, wherein said second virus-sized particles comprise virus-like particles of a second virus type.

[0348] 109. The method according to any one of example embodiment combination 1-108, wherein said virus-sized particle is modified to express a recombinant protein.

[0349] 110. The method according to example embodiment combination 109, wherein the flow cytometry does not detect light scatter.

[0350] 111. The method according to example embodiment combination 110, comprising preparing the fluid sample, said preparing the fluid sample comprising:

[0351] mixing the biological material to be evaluated for the presence of non-associated virus-sized particles with a fluorescent antibody stain; and

[0352] After mixing, fluorescent antibodies not bound to non-associated labeled particles are not removed from the fluid sample prior to flow cytometry.

[0353] 112. A method of preparing a product comprising virus-sized particles of a virus type, the method comprising:

[0354] A production process to prepare a purified product comprising virus-sized particles of the virus type, the production process comprising:

[0355] Generation of virus-sized particles in bioproduction operations;

[0356] harvesting from the bioproduction operation a crude product comprising virus-sized particles produced in the production;

[0357] purifying at least a portion of the crude product material to produce a purified product comprising viral-sized particles;

[0358] collecting a sample of the biological material from a stage of the production process during which the virus-sized particles are expected to be present in the biological material;

[0359] The sample is assessed for the presence of virus-sized particles having specific epitopes indicative of the virus type, the assessment comprising performing a method according to any one of example embodiment combinations 1-111.

[0360] 113. The method according to example embodiment combination 112, comprising performing said collecting a plurality of times to collect different said biological material samples to be evaluated from a plurality of different said stages, and performing said evaluation on each said collected biological material sample to be evaluated.

[0361] 114. A method according to example embodiment combination 113, wherein said plurality of different said stages comprises at least a first stage during said production or harvesting and a second stage during or after said purification.

[0362] 115. A fluid sample for injection into a flow cytometer for flow cytometric evaluation, comprising:

[0363] Aqueous liquid medium;

[0364] Non-associated labeled virus-sized particles in an aqueous liquid medium at a concentration of 1 x 10 5 Up to 1x 10 9 non-associated labeled particles / ml, wherein the non-associated labeled particles each comprise a virus-sized particle of a virus type having a specific epitope indicative of the virus type and a fluorescent antibody stain specific for binding directly or indirectly to the epitope; and

[0365] The concentration of unbound fluorescent antibody stain not bound to the non-associated labeled particles in the aqueous liquid medium ranged from 0.25 μg / mL to 10 μg / mL.

[0366] 116. The fluid sample according to example embodiment combination 115, wherein the concentration of unbound fluorescent antibody stain in the aqueous liquid medium ranges from 0.5 μg / ml to 10 μg / ml.

[0367] 117. The fluid sample according to example embodiment combination 115 or example embodiment combination 116, wherein the fluid sample comprises a total concentration of fluorescent antibody stain in the range of 0.25 μg / ml to 10 μg / ml.

[0368] 118. The fluid sample according to example embodiment combination 117, wherein the total concentration of the fluorescent antibody stain ranges from 0.5 μg / mL to 10 μg / mL.

[0369] 119. The fluid sample according to any one of example embodiment combinations 115-118, wherein the biological material in the fluid sample is a purified biological material from which larger size components have been removed, and the filter size is no greater than 2 microns.

[0370] 120. The fluid sample according to any one of example embodiment combinations 115-119, wherein the fluorescent antibody stain comprises fluorophores attached to antibody molecules, and the fluorescent antibody stain in the fluid sample contains an average of 3 to 8 attached fluorophores per antibody molecule.

[0371] 121. The fluid sample according to any one of example embodiment combination 115-120, wherein the antibody of the antibody stain is monoclonal.

[0372] 122. The fluid sample according to any one of example embodiment combination 115-120, wherein the antibodies of the antibody stain are polyclonal.

[0373] 123. The fluid sample according to any one of example embodiment combination 115-122, wherein said virus-sized particles are modified to express a recombinant protein.

[0374] 124. The fluid sample according to any one of example embodiment combinations 115-123, wherein:

[0375] The fluorescent antibody stain is a first fluorescent stain having a first fluorescent emission; and

[0376] The fluid sample contains a second fluorescent stain for nucleic acids, the second fluorescent stain having a second fluorescent emission different from the first fluorescent emission.

[0377] 125. The fluid sample according to any one of example embodiment combinations 115-123, wherein:

[0378] the fluorescent antibody stain is a first fluorescent antibody stain, the epitope is a first epitope, the fluorescence emission is a first fluorescence emission, the virus type is a first virus type and the non-associated labeled particle is a first non-associated labeled virus-sized particle;

[0379] The fluid sample contains a second fluorescent antibody stain that is different from the first fluorescent antibody stain and is capable of directly or indirectly binding to a second epitope that is different from the first epitope, the second epitope is indicative of a second virus type that is different from the first virus type, and the second fluorescent antibody stain has a second fluorescent emission response that is different from the first fluorescent emission response.

[0380] 126. The fluid sample according to example embodiment combination 125, wherein said virus-sized particle having a second epitope is a virus-like particle.

[0381] 127. The fluid sample according to any one of example embodiment combination 115-126, wherein said virus type is a baculovirus.

[0382] 128. The fluid sample according to any one of example embodiment combinations 115-126, wherein said virus type is adenovirus.

[0383] 129. The fluid sample according to any one of example embodiment combinations 115-126, wherein said virus type is an adeno-associated virus.

[0384] 130. The fluid sample according to any one of example embodiment combination 115-126, wherein said virus type is influenza virus.

[0385] For some other baculovirus applications:

[0386] 1B. A flow cytometric method for evaluating a sample of biological material for non-associated virus-sized particles of the baculovirus type, the method comprising:

[0387] Performing flow cytometry on a fluid sample containing at least a portion of the biological material sample, wherein the fluid sample contains a fluorescent antibody stain that can directly or indirectly bind to a baculovirus-type epitope, the flow cytometry comprising:

[0388] passing the fluid sample through a flow cell of a flow cytometer;

[0389] subjecting the fluid sample flowing through the flow cell to excitation radiation capable of inducing a fluorescent emission response from the fluorescent antibody stain; and

[0390] Radiation from the flow cell is detected within the wavelength range of the fluorescent emission and the detected radiation is evaluated to identify detection events indicative of passage of non-associated labeled virus-sized particles comprising the virus-sized particles of a baculovirus type bound to a portion of a fluorescent antibody stain through the flow cell.

[0391] 2B. A flow cytometry method according to example embodiment combination 1B, wherein the fluid sample injected into the flow cytometer contains a fluorescent antibody stain that is not bound to non-associated labeled particles in a concentration range of 0.25 (or 0.5) μg / mL to 10 μg / mL.

[0392] 3B. The flow cytometry method according to example embodiment combination 2B, wherein the fluid sample injected into the flow cytometer comprises a total concentration of fluorescent antibody staining reagent ranging from 0.25 (or 0.5) μg / mL to 10 μg / mL.

[0393] 4B. The flow cytometry method according to any of example embodiment combinations 1B-3B, wherein said epitope is a baculovirus gp64 envelope glycoprotein, and optionally said fluorescent antibody stain comprises an AcV1 monoclonal antibody.

[0394] 5B. The flow cytometry method according to any of example embodiment combinations 1B-4B, wherein the viral-sized particles comprise baculovirus particles.

[0395] 6B. The flow cytometry method according to example embodiment combination 5B, wherein the baculovirus particles express a recombinant protein.

[0396] 7B. The flow cytometry method according to any of example embodiment combinations 1B-6B, wherein:

[0397] The fluorescent antibody stain is a first fluorescent stain, the fluorescent emission is a first fluorescent emission, the detection is a first detection and the detection event is a first detection event;

[0398] The fluid sample comprises a second fluorescent stain for nucleic acids, the second fluorescent stain having a second fluorescent emission response to the excitation radiation different from the first fluorescent emission response when attached to the nucleic acids; and

[0399] The flow cytometry comprises a second detection that detects second radiation originating from the flow cell within a wavelength range of a second fluorescent emission and evaluates the detected second radiation to evaluate for detection events indicative of passage of virus-sized particles comprising nucleic acid stained with a second fluorescent stain; and

[0400] The results of the first detection and the second detection are compared to identify whether the first detection event and the second detection event occur coincident in time, which further indicates that the non-associated labeled particles comprising the virus-sized particles of the baculovirus type passed through the flow cell.

[0401] 8B. The flow cytometry method according to any of example embodiment combinations 1B-6B, wherein:

[0402] the fluorescent antibody stain is a first fluorescent antibody stain, the epitope is a first epitope, the fluorescence emission is a first fluorescence emission, the detection is a first detection, the virus type is a first virus type, the non-associated labeled particle is a first non-associated labeled virus-sized particle and the detection event is a first detection event;

[0403] The fluid sample comprises a second fluorescent antibody stain that is different from the first fluorescent antibody stain and is capable of binding directly or indirectly to a second epitope that is different from the first epitope, the second epitope being indicative of a second virus type that is different from a baculovirus, and the second fluorescent antibody stain has a second fluorescent emission response to the excitation radiation that is different from the first fluorescent emission response; and

[0404] The flow cytometry includes a second detection that detects second radiation originating from the flow cell within a wavelength range of a second fluorescent emission, and evaluates the detected second radiation to evaluate detection events indicative of a second non-associated labeled virus-sized particle passing through the flow cell, the second non-associated labeled virus-sized particle comprising a virus-sized particle having a second epitope and a second fluorescent antibody stain.

[0405] 9B. The flow cytometry method according to example embodiment combination 8B, wherein the virus-sized particles having the second epitope comprise virus-like particles.

[0406] 10B. The flow cytometry method according to example embodiment combination 8B or example embodiment combination 9B, wherein the second virus type is selected from the group consisting of a Rhabdovirus type and a Norovirus type.

[0407] 11B. The flow cytometry method according to any one of example embodiment combinations 1B-6B, wherein the epitope is a first epitope, the flow cytometry is a first flow cytometry, the fluid sample is a first fluid sample comprising a first portion of a biological material sample, the non-associated labeled particles are first non-associated labeled particles and the excitation radiation is a first excitation radiation, and the method comprises:

[0408] performing flow cytometry on a second fluid sample comprising a second portion of the biological material sample, wherein the fluid sample comprises a second fluorescent antibody stain different from the first fluorescent antibody stain, and the second fluorescent antibody stain is capable of directly or indirectly binding to a second epitope different from the first epitope, the second epitope being indicative of a second virus type different from a baculovirus, and the second flow cytometry comprises:

[0409] passing a second fluid sample through a flow cell of a flow cytometer;

[0410] subjecting a second fluid sample flowing through the flow cell to a second excitation radiation that is the same as or different from the first excitation radiation and that is capable of inducing a second fluorescent emission response from the second fluorescent antibody stain that is different from the first fluorescent emission response; and

[0411] Radiation from the flow cell is detected within the wavelength range of the fluorescent emission and the detected radiation is evaluated to identify detection events indicative of passage of a second non-associated labeled virus-sized particle through the flow cell, the second non-associated labeled virus-sized particle comprising a virus-sized particle having a second epitope and a second fluorescent antibody stain.

[0412] 12B. The flow cytometry method according to example embodiment combination 11B, wherein:

[0413] The first and second fluid samples each contain at least two different fluorescent antibody stains to directly or indirectly bind to two different epitopes; and

[0414] The first and second fluid samples each include at least one fluorescent antibody stain that is not present in the other fluid sample.

[0415] 13B. A flow cytometry method according to example embodiment combination 12B, wherein at least two fluorescent antibody stains of each of the fluid samples target detection of at least two different types of virus-sized particles in the fluid samples, and at least one of the types of particles is different between the first sample fluid and the second sample fluid.

[0416] 14B. The flow cytometric method according to any of example embodiment combinations 1B-13B, wherein the biological material sample is a sample collected from a stage of a production operation for producing baculovirus particles, during which stage virus-sized particles of the baculovirus type are expected to be present in the biological material.

[0417] 15B. A flow cytometric method for preparing a product comprising virus-sized particles of the baculovirus type, the method comprising:

[0418] A production process to prepare a purified product comprising virus-sized particles of the baculovirus type, the production process comprising:

[0419] Generation of virus-sized particles in bioproduction operations;

[0420] harvesting a crude product from the bioproduction operation, which comprises virus-sized particles produced in the production operation;

[0421] purifying at least a portion of the crude product material to produce a purified product comprising viral-sized particles;

[0422] collecting a sample of the biological material from a stage of the production process during which the virus-sized particles are expected to be present in the biological material;

[0423] The sample is evaluated for the presence of viral-sized particles having an epitope indicative of a baculovirus type, the evaluating comprising performing a method according to any of example embodiment combinations 1B-13B.

[0424] 16B. The flow cytometry method according to example embodiment combination 15B, comprising performing said collecting a plurality of times to collect different said biological material samples to be evaluated from a plurality of different said stages, and performing said evaluation on each of said collected biological material samples to be evaluated.

[0425] 17B. The flow cytometry method according to example embodiment combination 16B, wherein the plurality of different said stages comprises at least a first stage during said generation or harvesting and a second stage during or after said purification.

[0426] 18B. The flow cytometry method according to any of example embodiment combinations 1B-17B, wherein the biological material in the fluid sample is a purified biological material from which larger size components have been removed, and the filter size is no greater than 2 microns.

[0427] 19B. The flow cytometry method according to any of example embodiment combinations 1B-18B, wherein the fluid sample entering the flow cytometer has a concentration of non-associated labeled particles in the range of 1 x 10 5 Up to 1x 10 9 Particles / ml.

[0428] 20B. The flow cytometry method according to any of example embodiment combinations 1B-19B, wherein said fluorescent antibody stain comprises fluorophores attached to antibody molecules, and the fluorescent antibody stain in the fluid sample comprises an average of 3 to 8 attached fluorophores per said antibody molecule.

[0429] 21B. The flow cytometry method according to any of example embodiment combinations 1B-20B, wherein the antibody to the fluorescent stain is monoclonal.

[0430] 22B. The flow cytometry method according to any of example embodiment combinations 1B-21B, wherein said flow cytometry comprises flowing said fluid sample through a flow cell at a fluid sample flow rate in the range of 250 to 3000 nanoliters per minute.

[0431] 23B. A flow cytometry method according to any one of example embodiment combinations 1B-22B, comprising:

[0432] The fluid sample is prepared by mixing the biological material to be evaluated for the presence of non-associated virus-sized particles with a fluorescent antibody stain.

[0433] 24B. A flow cytometry method according to example embodiment combination 23B, wherein preparing the fluid sample includes, prior to mixing, purifying a crude sample of biological material to prepare the biological material for the fluid sample for flow cytometry, the purification including filtering out particles of the crude sample at a filter size no greater than 2 microns, and including spinning the chromatography in a centrifuge to remove at least a portion of impurities smaller than the size of a virus.

[0434] 25B. A flow cytometry method according to example embodiment combination 23B or example embodiment combination 24B, wherein preparing the fluid sample includes, after mixing and prior to flow cytometry, not removing fluorescent antibody stain that is not bound to non-associated labeled particles from the fluid sample.

[0435] 26B. The flow cytometry method according to any of example embodiment combination 23B-25B, wherein the fluorescent antibody stain comprises a biotinylated antibody and fluorophore-conjugated streptavidin.

[0436] 27B. The flow cytometry method according to example embodiment combination 26B, wherein the fluorophore-conjugated streptavidin is attached to the biotinylated antibody when provided to the mixing step.

[0437] 28B. The flow cytometry method according to example embodiment combination 27B, wherein the fluorophore-conjugated streptavidin and the biotinylated antibody are provided in separate preparations for the mixing step, and the fluorophore-conjugated streptavidin attaches to the biotinylated antibody in solution during the mixing process.

[0438] 29B. The flow cytometry method according to any of example embodiment combinations 1B-28B, wherein the flow cytometry does not detect light scatter.

[0439] 30B. A flow cytometry method according to example embodiment combination 3B, wherein the fluid sample injected into the flow cytometer has a concentration of non-associated labeled particles in the range of 1 x 10 5 Up to 1x 10 9Particles / ml.

[0440] 31B. The flow cytometry method according to example embodiment combination 30B, wherein said fluorescent antibody stain comprises fluorophores attached to antibody molecules, and the fluorescent antibody stain in the fluid sample comprises an average of 3 to 8 attached fluorophores per said antibody molecule.

[0441] 32B. A flow cytometry method according to example embodiment combination 31B, wherein the fluorescent antibody stain is a first fluorescent stain and the fluid sample contains a second fluorescent stain having a second fluorescent emission response caused by excitation radiation, the second fluorescent emission response being different from the first fluorescent emission response of the first fluorescent stain.

[0442] 33B. The flow cytometry method according to example embodiment combination 32B, wherein the second fluorescent stain comprises a fluorescent nucleic acid stain that is not specific to the particle type.

[0443] 34B. The flow cytometry method according to example embodiment combination 32B, wherein:

[0444] the non-associated labeled particle is a first non-associated labeled particle, the epitope is a first epitope, the viral size particle is a first viral size particle, the baculovirus type is a first viral type and the non-associated labeled particle is a first non-associated labeled particle;

[0445] The second fluorescent stain is a second fluorescent antibody stain different from the first fluorescent antibody stain and is capable of binding to a second virus size particle having a second epitope indicative of a second virus type different from the first virus type to form a second non-associated labeled virus size particle; and

[0446] The method includes detecting radiation from the flow cell within the wavelength range of a second fluorescent emission and evaluating the detected radiation to identify detection events indicative of passage of a particle having a second unassociated label through the flow cell.

[0447] 35B. The flow cytometry method according to example embodiment combination 34B, wherein the second fluorescent emission has a peak wavelength that differs from the peak wavelength of the first fluorescent emission by at least 20 nanometers, and the flow cytometry includes independently detecting at least the first and second fluorescent emissions and not detecting light scatter.

[0448] 36B. The flow cytometry method according to example embodiment combination 35B, wherein the second virus size particles comprise virus-like particles of a second virus type.

[0449] 37B. The flow cytometry method according to example embodiment combination 3 IB, wherein the epitope is a baculovirus gp64 envelope glycoprotein and the fluorescent antibody stain comprises an AcV1 monoclonal antibody.

[0450] 38B. The flow cytometry method according to any of example embodiment combination 30B-37B, wherein the virus-sized particles comprise a baculovirus modified to express a recombinant protein.

[0451] 39B. The flow cytometry method according to example embodiment combination 38B, wherein the flow cytometry does not detect light scatter.

[0452] 40B. The flow cytometry method according to example embodiment combination 38B, comprising preparing the fluid sample, the preparing the fluid sample comprising:

[0453] mixing the biological material to be evaluated for the presence of non-associated virus-sized particles with a fluorescent antibody stain; and

[0454] After mixing, fluorescent antibodies not bound to non-associated labeled particles are not removed from the fluid sample prior to flow cytometry.

[0455] 41B. A fluid sample for injection into a flow cytometer for flow cytometric evaluation, comprising:

[0456] Aqueous liquid medium;

[0457] Non-associated labeled virus-sized particles in an aqueous liquid medium at a concentration of 1 x 10 5 Up to 1x 10 9 non-associated labeled particles / ml, wherein the non-associated labeled particles each comprise a virus-sized particle of a baculovirus type having an epitope indicative of a baculovirus type and a fluorescent antibody stain specific for direct or indirect binding to the epitope; and

[0458] The concentration of unbound fluorescent antibody stain not bound to the non-associated labeled particles in the aqueous liquid medium ranged from 0.5 μg / mL to 10 μg / mL.

[0459] 42B. The fluid sample according to example embodiment combination 41B, wherein the fluid sample comprises a total concentration of fluorescent antibody stain in the range of 0.5 μg / mL to 10 μg / mL.

[0460] 43B. The fluid sample according to example embodiment combination 41B or example embodiment combination 42B, wherein the biological material in the fluid sample is a purified biological material from which larger size components have been removed, and the filtration size is no greater than 2 microns.

[0461] 44B. The fluid sample according to any of example embodiment combinations 41B-43B, wherein said non-associated labeled particles have a maximum cross-sectional dimension no greater than 600 nanometers.

[0462] 45B. The fluid sample according to any of example embodiment combinations 41B-44B, wherein the fluorescent antibody stain comprises fluorophores attached to antibody molecules, and the fluorescent antibody stain in the fluid sample comprises an average of 3 to 8 attached fluorophores per antibody molecule.

[0463] 46B. The fluid sample according to any of example embodiment combinations 41B-45B, wherein the antibody of the antibody stain is monoclonal.

[0464] 47B. The fluid sample according to any of example embodiment combinations 41B-46B, wherein said virus-sized particles comprise a baculovirus modified to express a recombinant protein.

[0465] 48B. The fluid sample according to any one of example embodiment combinations 41B-47B, wherein said epitope is a baculovirus gp64 envelope glycoprotein and said fluorescent antibody stain comprises an AcV1 monoclonal antibody.

[0466] 49B. The fluid sample according to any one of example embodiment combinations 41B-48B, wherein the fluorescent antibody stain comprises a biotinylated antibody and fluorophore-conjugated streptavidin.

[0467] 50B. The fluid sample according to any one of example embodiment combinations 41B-49B, wherein:

[0468] The fluorescent antibody stain is a first fluorescent stain having a first fluorescent emission; and

[0469] The fluid sample contains a second fluorescent stain for nucleic acids, the second fluorescent stain having a second fluorescent emission different from the first fluorescent emission.

[0470] 51B. The fluid sample of any one of example embodiment combinations 41B-49B, wherein:

[0471] the fluorescent antibody stain is a first fluorescent antibody stain, the epitope is a first epitope, the fluorescence emission is a first fluorescence emission, the virus type is a first virus type and the non-associated labeled particle is a first non-associated labeled virus-sized particle;

[0472] The fluid sample comprises a second fluorescent antibody stain that is different from the first fluorescent antibody stain and is capable of directly or indirectly binding to a second epitope that is different from the first epitope, the second epitope is indicative of a second virus type that is different from a baculovirus, and the second fluorescent antibody stain has a second fluorescent emission response that is different from the first fluorescent emission response.

[0473] 52B. The fluid sample of combination 51B according to example embodiment, wherein the virus-sized particles having the second epitope are virus-like particles.

[0474] 53B. The fluid sample according to example embodiment combination 51B or example embodiment combination 52B, wherein the second virus type is selected from the group consisting of a Rhabdovirus type and a Norovirus type.

[0475] 54B. The fluid sample according to example embodiment combination 42B, wherein the fluorescent antibody stain comprises fluorophores attached to antibody molecules, and the fluorescent antibody stain in the fluid sample comprises an average of 3 to 8 attached fluorophores per antibody molecule.

[0476] 55B. The fluid sample according to example embodiment combination 54B, wherein the fluorescent antibody stain comprises a biotinylated antibody and a fluorophore-conjugated streptavidin.

[0477] 56B. The fluid sample of combination 54B according to example embodiment, wherein:

[0478] The fluorescent antibody stain is a first fluorescent stain having a first fluorescent emission; and

[0479] The fluid sample contains a second fluorescent stain for nucleic acids, the second fluorescent stain having a second fluorescent emission different from the first fluorescent emission.

[0480] 57B. The fluid sample of combination 54B according to example embodiment, wherein:

[0481] the fluorescent antibody stain is a first fluorescent antibody stain, the epitope is a first epitope, the fluorescence emission is a first fluorescence emission, the virus type is a first virus type and the non-associated labeled particle is a first non-associated labeled virus-sized particle;

[0482] The fluid sample comprises a second fluorescent antibody stain that is different from the first fluorescent antibody stain and is capable of directly or indirectly binding to a second epitope that is different from the first epitope, the second epitope is indicative of a second virus type that is different from a baculovirus and the second fluorescent antibody stain has a second fluorescent emission response that is different from the first fluorescent emission response.

[0483] 58B. The fluid sample according to example embodiment combination 57B, wherein the virus-sized particle having a second epitope is a virus-like particle.

[0484] 59B. The fluid sample according to any of example embodiment combinations 54B-58B, wherein said virus-sized particles comprise a baculovirus modified to express a recombinant protein.

[0485] 60B. The fluid sample according to example embodiment combination 59B, wherein the epitope is a baculovirus gp64 envelope glycoprotein and the fluorescent antibody stain comprises an AcV1 monoclonal antibody.

[0486] 1C. The method according to any one of the example embodiment combinations, wherein the flow cytometry comprises:

[0487] counting detection events as individuals of non-associated labeled particles that pass through the flow cell to determine a count of non-associated labeled particles in a volume of fluid sample passing through the flow cell;

[0488] determining a volume of the fluid sample passing through the flow cell corresponding to the count; and

[0489] The count of non-associated labeled particles is used to determine the concentration of non-associated labeled particles in the fluid sample volume passing through the flow cell.

[0490] 2C. The method according to example embodiment combination 1C, wherein the flow cytometry comprises:

[0491] counting the unassociated labeled particles in real time based on the detection of radiation corresponding to the detection event; and

[0492] The concentration is determined in real time based on the volume of fluid sample passing through the flow cell.

[0493] 3C. A method according to example embodiment combination 1C or example embodiment combination 2C, wherein determining the volume of the fluid sample passing through the flow cell includes measuring the flow rate of the fluid sample to the flow cell in real time using a flow sensor, and integrating the resulting flow rate measurement data over time.

[0494] 4C. The method according to any of example embodiment combinations 1C-3C, wherein identification of a detection event indicative of a particle with an unassociated label passing through the flow cell is determined without information associated with light scattering detections.

[0495] 1D. A method for evaluating a sample of biological material for non-associated virus-sized particles having a specific epitope, the method comprising:

[0496] performing flow cytometry on a fluid sample comprising at least a portion of the biological material sample, wherein the fluid sample comprises a fluorescent antibody stain that can directly or indirectly bind to the specific epitope to form particles comprising virus-sized particles having the epitope and non-associated labeled particles of the fluorescent antibody stain,

[0497] The fluid sample injected into the flow cytometer during flow cytometry contains fluorescent antibody stain that is not bound to non-associated labeled particles in a concentration range of 0.5 μg / mL to 10 μg / mL.

[0498] 2D. A method for evaluating a sample of biological material for non-associated virus-sized particles having a specific epitope, the method comprising:

[0499] performing flow cytometry on a fluid sample comprising at least a portion of the biological material sample, wherein the fluid sample comprises a fluorescent antibody stain that can directly or indirectly bind to the specific epitope to form particles comprising virus-sized particles having the epitope and non-associated labeled particles of the fluorescent antibody stain, and

[0500] Prior to flow cytometry, the fluid sample was prepared including:

[0501] mixing the biological material to be assessed for the presence of non-associated particles with a fluorescent antibody stain that binds directly or indirectly to the epitope to form non-associated labeled virus-sized particles,

[0502] After mixing, fluorescent antibodies not bound to non-associated labeled particles are not removed from the fluid sample prior to flow cytometry.

[0503] 3D. A method for evaluating a sample of biological material for non-associated virus-sized particles having a specific epitope, the method comprising:

[0504] performing flow cytometry on a fluid sample comprising at least a portion of the biological material sample, wherein the fluid sample comprises a fluorescent antibody stain that can directly or indirectly bind to the specific epitope to form particles comprising virus-sized particles having the epitope and non-associated markers of the fluorescent antibody stain;

[0505] The flow cytometry described herein does not detect light scatter.

[0506] 4D. The method according to example embodiment 3D, wherein the flow cytometry comprises detecting only fluorescence emission.

[0507] 5D. A method for evaluating a sample of biological material for non-associated virus-sized particles having a specific epitope, the method comprising:

[0508] performing flow cytometry on a fluid sample comprising at least a portion of the biological material sample, wherein the fluid sample comprises a fluorescent antibody stain that can directly or indirectly bind to the specific epitope to form particles comprising virus-sized particles having the epitope and non-associated markers of the fluorescent antibody stain;

[0509] Wherein the fluorescent antibody stain comprises fluorophores attached to antibody molecules, each antibody molecule comprises an average of 3 to 8 attached fluorophores.

[0510] 6D. A method for evaluating a sample of biological material for non-associated virus-sized particles having a specific epitope, the method comprising:

[0511] performing flow cytometry on a fluid sample comprising at least a portion of the biological material sample, wherein the fluid sample comprises a fluorescent antibody stain that can directly or indirectly bind to the specific epitope to form particles comprising virus-sized particles having the epitope and non-associated markers of the fluorescent antibody stain;

[0512] wherein the fluorescent antibody stain is a first fluorescent stain having a first fluorescent emission response, and the fluid sample contains a second fluorescent stain having a second fluorescent emission response, the second fluorescent emission response being different from the first fluorescent emission response of the first fluorescent stain, and the flow cytometry comprises detecting radiation within a first wavelength range of the first fluorescent emission response and within a second wavelength range of the second fluorescent emission response.

[0513] 7D. The method of example embodiment 6D, wherein the second fluorescent stain comprises a fluorescent nucleic acid stain that is not specific to the particle type.

[0514] 8D. The method according to example embodiment 6D, wherein the epitope is a first epitope and the second fluorescent stain comprises a second fluorescent antibody stain that binds to a second epitope different from the first epitope.

[0515] 9D. The method according to example embodiment 6D, wherein:

[0516] The non-associated particle is a first non-associated particle, the epitope is a first epitope, the non-associated particle is a first particle type and the non-associated labeled particle is a first non-associated labeled particle;

[0517] The second fluorescent stain is a second fluorescent antibody stain that is different from the first fluorescent antibody stain and is capable of binding to a second non-associated virus-sized particle to form a second non-associated labeled virus-sized particle, wherein the second non-associated virus-sized particle has a second epitope indicative of a second particle type that is different from the first particle type.

[0518] 10D. The method according to example embodiment 6D, wherein the second fluorescent emission has a peak wavelength that is at least 20 nanometers different from the peak wavelength of the first fluorescent emission.

[0519] 11D. The method according to any of example embodiments 1D-10D, wherein the flow cytometry comprises:

[0520] passing the fluid sample through a flow cell of a flow cytometer;

[0521] subjecting the fluid sample flowing through the flow cell to excitation radiation capable of inducing a fluorescent emission response from the fluorescent antibody stain; and

[0522] Radiation from the flow cell is detected within the wavelength range of the fluorescent emission and the detected radiation is evaluated to identify detection events indicative of passage of an unassociated labeled virus-sized particle comprising the virus-sized particle having the epitope and the fluorescent antibody stain through the flow cell.

[0523] 12D. The method according to any of example embodiments 1D-10D, wherein the fluid sample injected into the flow cytometer during flow cytometry comprises a total concentration of fluorescent antibody stain in the range of 0.5 μg / mL to 10 μg / mL.

[0524] 13D. The method according to any of example embodiments 1D-10D, wherein the fluid sample injected into the flow cytometer during flow cytometry has a concentration of non-associated labeled particles of at most 1 x 109 particles / ml.

[0525] 14D. The method according to any of example embodiments 1D-10D, wherein the fluid sample injected into the flow cytometer during flow cytometry has a concentration of non-associated labeled particles in the range of 1 x 105 to 1 x 109 particles / ml.

[0526] 15D. A method of preparing a product comprising virus-sized particles of a virus type, the method comprising:

[0527] manufacturing a process to produce a purified product comprising virus-sized particles of the virus type;

[0528] collecting a sample of biological material from a stage of the production process during which the virus-sized particles are expected to be present in the biological material; and

[0529] The sample is assessed for the presence of virus-sized particles having specific epitopes indicative of the virus type, the assessing comprising performing a method according to any one of example embodiments 1D-10D.

[0530] 16D. The method according to example embodiment 15D comprises performing said collecting a plurality of times to collect different said biomaterial samples to be evaluated from a plurality of different said production process stages, and performing said evaluation on each said collected biomaterial sample to be evaluated.

[0531] 17D. The method according to example embodiment 16D, wherein the production process comprises:

[0532] Generation of virus-sized particles in bioproduction operations;

[0533] harvesting from the bioproduction operation a crude product comprising virus-sized particles produced in the production;

[0534] At least a portion of the crude product material is purified to produce a purified product comprising viral-sized particles.

[0535] 18D. The method according to example embodiment 17D, wherein said plurality of different said stages comprises at least a first stage during said production or harvesting and a second stage during or after said purification.

[0536] 19D. The method according to any of example embodiments 1D-10D, wherein the flow cytometry comprises flowing the fluid sample through a flow cell of a flow cytometer at a fluid sample flow rate in the range of 250 to 3000 nanoliters per minute.

[0537] 20D. The method according to any of example embodiments 2D-10D, wherein the fluid sample injected into the flow cytometer contains a concentration of fluorescent antibody stain that is not bound to non-associated labeled particles in the range of 0.5 μg / mL to 10 μg / mL.

[0538] 21D. The method according to any of example embodiments 1D and 3D-10D, comprising:

[0539] Preparing the fluid sample comprises mixing the biological material to be evaluated for the presence of non-associated particles with a fluorescent antibody stain that binds directly or indirectly to the epitope to form non-associated labeled virus-sized particles; and

[0540] After mixing, fluorescent antibody stain not bound to non-associated labeled particles is not removed from the fluid sample prior to flow cytometry.

[0541] 22D. A fluid sample for injection into a flow cytometer for flow cytometric evaluation, comprising:

[0542] Aqueous liquid medium;

[0543] Non-associated labeled virus-sized particles in an aqueous liquid medium at a concentration of up to 1 x 109 non-associated labeled particles / ml, wherein the non-associated labeled particles each comprise a virus-sized particle of a virus type having a particular epitope indicative of the virus type and a fluorescent antibody stain specific for binding directly or indirectly to the epitope; and

[0544] The concentration of unbound fluorescent antibody stain not bound to the non-associated labeled particles in the aqueous liquid medium ranged from 0.5 μg / mL to 10 μg / mL.

[0545] 23D. The fluid sample according to example embodiment 22D, wherein the fluid sample comprises a total concentration of fluorescent antibody stain in the range of 0.5 μg / mL to 10 μg / mL.

[0546] 24D. A fluid sample according to example embodiment 22D, wherein:

[0547] The fluorescent antibody stain is a first fluorescent stain having a first fluorescent emission; and

[0548] The fluid sample contains a second fluorescent stain for nucleic acids, the second fluorescent stain having a second fluorescent emission different from the first fluorescent emission.

[0549] 25D. A fluid sample according to example embodiment 22D, wherein:

[0550] The fluorescent antibody stain is a first fluorescent antibody stain having a first fluorescent emission, and the epitope is a first epitope;

[0551] The fluid sample comprises a second fluorescent antibody stain having a second fluorescent emission different from the first fluorescent emission; and

[0552] The second fluorescent stain comprises a second fluorescent antibody stain capable of binding to a second epitope different from the first epitope.

[0553] 26D. A fluid sample according to example embodiment 22D, wherein:

[0554] the fluorescent antibody stain is a first fluorescent antibody stain, the epitope is a first epitope, the fluorescence emission is a first fluorescence emission, the virus type is a first virus type and the non-associated labeled particle is a first non-associated labeled virus-sized particle;

[0555] The fluid sample contains a second fluorescent antibody stain that is different from the first fluorescent antibody stain and is capable of directly or indirectly binding to a second epitope that is different from the first epitope, the second epitope is indicative of a second virus type that is different from the first virus type, and the second fluorescent antibody stain has a second fluorescent emission response that is different from the first fluorescent emission response.

[0556] 27D. The fluid sample according to example embodiment 22D, wherein the fluid sample has a concentration of non-associated labeled particles in the range of 1 x 105 to 1 x 109 particles / ml.

[0557] 28D. The method or fluid sample of any of example embodiments 1D-10D and 22D-27D, wherein the non-associated labeled particles have a maximum cross-sectional dimension ranging from 10 nanometers to 2 micrometers.

[0558] 29D. The method or fluid sample of any one of example embodiments 1D-4D, 6D-10D, and 22D-27D, wherein the fluorescent antibody stain comprises fluorophores attached to antibody molecules, each antibody molecule comprising an average of 3 to 8 attached fluorophores.

[0559] 30D. The method or fluid sample according to any of example embodiments 1D-10D and 22D-27D, wherein the virus-sized particles are exosomes.

[0560] 31D. The method or fluid sample according to any of example embodiments 1D-10D and 22D-27D, wherein the virus-sized particles are virus-like particles.

[0561] 32D. The method or fluid sample according to any of example embodiments 1D-10D and 22D-27D, wherein the virus-sized particles are virus particles.

[0562] 33D. The method or fluid sample according to any of example embodiments 1D-10D and 22D-27D, wherein the virus type is baculovirus.

[0563] 34D. The method or fluid sample according to any of example embodiments 1D-10D and 22D-27D, wherein the virus type is Norovirus.

[0564] 35D. The method or fluid sample according to any of example embodiments 1D-10D and 22D-27D, wherein the virus type is enterovirus.

[0565] 36D. The method or fluid sample according to any of example embodiments 1D-10D and 22D-27D, wherein the virus type is influenza virus.

[0566] 37D. The method or fluid sample according to any of example embodiments 1D-10D and 22D-27D, wherein the virus-sized particle is modified to express a recombinant protein.

[0567] 38D. A method for preparing a fluorescent antibody stain for staining virus-sized particles having a target epitope, the method comprising:

[0568] Fluorophores are directly or indirectly attached to antibody molecules that are targeted to bind to a target epitope in an aqueous liquid medium at a pH of pH 7 to pH 8, and the average number of fluorophores attached per antibody molecule ranges from 3 to 8.

[0569] 39D. The method according to example embodiment 38D, wherein the aqueous liquid medium comprises a buffer solution.

[0570] 40D. The method according to example embodiment 39D, wherein the buffer solution is a phosphate buffer solution.

[0571] The foregoing discussion of the present invention and its different aspects is presented for the purpose of illustration and description. The foregoing is not intended to limit the present invention to only the form specifically disclosed herein. Therefore, changes and modifications commensurate with the above teachings and the technology and knowledge of the relevant field are within the scope of the present invention. The embodiments described above are further used to explain the best known way to practice the present invention and enable other technicians in the field to utilize the present invention with such or other embodiments and various modifications required for the specific application or use of the present invention. Please note that the attached claims should be understood to include alternative embodiments to the extent permitted by the prior art. Although the description of the present invention has included a description of one or more possible embodiments and certain changes and modifications, after understanding the present invention, other changes and modifications are within the scope of the present invention, such as changes and modifications within the scope of the technology and knowledge of the field. The present invention is intended to obtain the rights and interests of alternative embodiments within the permitted scope, including the required alternative, interchangeable and / or equivalent structure, function, scope or step, regardless of whether such alternative, interchangeable and / or equivalent structure, function, scope or step is disclosed herein, and the present invention is not intended to donate any patentable subject matter. Moreover, any feature described and claimed with respect to any disclosed variation may be combined with any one or more of any other variation in any combination, even though such features may be technically incompatible, and all such combinations are included within the scope of the invention. The description of one or more features in a particular combination does not exclude the inclusion of additional one or more features. The processing steps and sequencing are for illustration only, and such examples do not exclude the inclusion of other steps or other sequences of steps. Additional steps may be included between the illustrated processing steps or before or after any illustrated processing step.

[0572] The terms "comprising" and grammatical variations of these terms are intended to be inclusive and non-limiting, as the use of such terms specifies the presence of some conditions or features, but does not exclude any other conditions or features. The use of the terms "comprising" and grammatical variations of these terms to refer to the presence of one or more components, subcomponents or materials also includes and is intended to disclose more specific embodiments, wherein the term "comprising" (or variations of such terms) is replaced by the narrower terms "consisting essentially of" or "consisting of" or "consisting only of" (or appropriate grammatical variations of such narrower terms). For example, the statement that something "comprises" certain elements is also intended to include and disclose more specific narrower embodiments of objects "consisting essentially of" certain elements and objects "consisting of" certain elements. Examples of various features have been provided for the purpose of explanation, and the terms "examples", "for example", etc. refer to exemplary examples, which are not limiting and should not be interpreted or understood as limiting the features to any specific examples. The term "at least" followed by a number (e.g., at least one) means that the number can be greater than the number shown. The term "at least a portion" means all or a portion less than all. The term "at least a portion" means a portion of all or less than all.

[0573] For example, a "portion" or material of a sample of biological material refers to some component or ingredient of such material, including aliquots of the same composition of the material and processed portions of the material that no longer have the same composition but have one or more components from the material and may be mixed with other components that are not derived from the material (e.g., buffer solutions, reagents). For example, a fluid sample containing biological material to be subjected to flow cytometry includes a portion of the collected crude sample of biological material even if the fluid sample only contains some purified biological components separated from the crude sample. As another example, if a batch of fluid samples prepared to include some biological material for evaluation is divided into separate aliquots for separate flow cytometric runs of the separate aliquots, each such aliquot includes a portion of the biological material from the batch and includes a portion of the biological material from the crude sample that may have been purified.

Claims

1. A method for evaluating a sample of biological material for non-associated virus-sized particles having a specific epitope, the method comprising: performing flow cytometry on a fluid sample comprising at least a portion of the biological material sample, wherein the fluid sample comprises a fluorescent antibody stain capable of directly or indirectly binding to the specific epitope to form particles comprising a virus-sized particle having the epitope and a non-associated marker of the fluorescent antibody stain; wherein the fluorescent antibody stain is a first fluorescent stain having a first fluorescent emission response, and the fluid sample contains a second fluorescent stain having a second fluorescent emission response, the second fluorescent emission response being different from the first fluorescent emission response of the first fluorescent stain, and the flow cytometry comprises detecting radiation within a first wavelength range of the first fluorescent emission response and within a second wavelength range of the second fluorescent emission response.

2. The method of claim 1, wherein the second fluorescent stain comprises a fluorescent nucleic acid stain that is not specific to the particle type.

3. The method according to claim 1, wherein the epitope is a first epitope and the second fluorescent stain comprises a second fluorescent antibody stain capable of binding to a second epitope different from the first epitope.

4. The method according to claim 1, wherein: The non-associated particle is a first non-associated particle, the epitope is a first epitope, the non-associated particle is a first particle type and the non-associated labeled particle is a first non-associated labeled particle; The second fluorescent stain is a second fluorescent antibody stain different from the first fluorescent antibody stain, and the second fluorescent antibody stain is capable of binding to a second non-associated virus-sized particle to form a second non-associated labeled virus-sized particle, and the second non-associated virus-sized particle has a second epitope indicative of a second particle type different from the first particle type.

5. The method of claim 1, wherein the second fluorescent emission has a peak wavelength that is at least 20 nanometers different from the peak wavelength of the first fluorescent emission.

6. A method for evaluating a sample of biological material for non-associated virus-sized particles having a specific epitope, the method comprising: performing flow cytometry on a fluid sample comprising at least a portion of the biological material sample, wherein the fluid sample comprises a fluorescent antibody stain capable of directly or indirectly binding to the specific epitope to form particles comprising virus-sized particles having the epitope and non-associated markers of the fluorescent antibody stain, and Prior to flow cytometry, the fluid sample is prepared, including: mixing the biological material to be assessed for the presence of non-associated particles with a fluorescent antibody stain capable of binding directly or indirectly to the epitope to form non-associated labeled virus-sized particles, After mixing, fluorescent antibody stain not bound to non-associated labeled particles is not removed from the fluid sample prior to flow cytometry.

7. A method for evaluating a sample of biological material for non-associated virus-sized particles having a specific epitope, the method comprising: performing flow cytometry on a fluid sample comprising at least a portion of the biological material sample, wherein the fluid sample comprises a fluorescent antibody stain capable of directly or indirectly binding to the specific epitope to form particles comprising a virus-sized particle having the epitope and a non-associated marker of the fluorescent antibody stain; The flow cytometry described herein does not detect light scatter.

8. The method according to claim 7, wherein the flow cytometry comprises detecting only fluorescence emission.

9. A method for evaluating a sample of biological material for non-associated virus-sized particles having a specific epitope, the method comprising: performing flow cytometry on a fluid sample comprising at least a portion of the biological material sample, wherein the fluid sample comprises a fluorescent antibody stain capable of directly or indirectly binding to the specific epitope to form particles comprising a virus-sized particle having the epitope and a non-associated marker of the fluorescent antibody stain; Wherein the fluorescent antibody stain comprises fluorophores attached to antibody molecules, each antibody molecule comprises an average of 3 to 8 attached fluorophores.

10. The method according to any one of claims 1 to 9, wherein the flow cytometry comprises: allowing the fluid sample to flow through a flow cell of a flow cytometer; subjecting the fluid sample flowing through the flow cell to excitation radiation capable of inducing a fluorescent emission response from a fluorescent antibody stain; and Radiation from the flow cell is detected within the wavelength range of the fluorescent emission and the detected radiation is evaluated to identify detection events indicative of passage of an unassociated labeled virus-sized particle comprising the virus-sized particle having the epitope and the fluorescent antibody stain through the flow cell.

11. The method according to any one of claims 1 to 9, wherein the fluid sample injected into the flow cytometer during the flow cytometry comprises the fluorescent antibody stain at a total concentration ranging from 0.5 μg / ml to 10 μg / ml.

12. The method according to any one of claims 1 to 9, wherein the fluid sample injected into the flow cytometer during the flow cytometry has a concentration of the non-associated labeled particles of at most 1 x 10 9 Particles / ml.

13. The method according to any one of claims 1 to 9, wherein the fluid sample injected into the flow cytometer during the flow cytometry has a concentration of the non-associated labeled particles in the range of 1 x 10 5 Up to 1x 10 9 Particles / ml.

14. A method for preparing a product comprising virus-sized particles of a virus type, the method comprising: manufacturing a process to produce a purified product comprising virus-sized particles of the virus type; collecting a sample of biological material from a stage of the production process during which the virus-sized particles are expected to be present in the biological material; and The sample is assessed for the presence of virus-sized particles having specific epitopes indicative of the virus type, said assessing comprising performing a method according to any one of claims 1-9.

15. The method according to claim 14, wherein the production process comprises: generating said virus-sized particles in a bioproduction operation; harvesting from said bioproduction operation a crude product comprising virus-sized particles produced in said production; At least a portion of the crude product material is purified to produce a purified product comprising viral-sized particles.

16. The method according to claim 15, comprising performing said collecting a plurality of times to collect different said biological material samples to be evaluated from a plurality of different said production process stages, and performing said evaluation on each said collected biological material sample to be evaluated.

17. The method according to claim 16, wherein said plurality of different said stages comprises at least a first stage during said production or harvesting and a second stage during or after said purification.

18. The method according to any one of claims 1 to 9, wherein the flow cytometry comprises flowing the fluid sample through a flow cell of a flow cytometer at a fluid sample flow rate in the range of 250 to 3000 nanoliters per minute.

19. The method according to any one of claims 1 to 9, wherein the fluid sample injected into the flow cytometer contains a concentration of fluorescent antibody stain not bound to non-associated labeled particles in the range of 0.5 μg / ml to 10 μg / ml.

20. A method according to any one of claims 1 to 5 and 7 to 9, comprising: preparing the fluid sample, comprising mixing the biological material to be assessed for the presence of non-associated particles with a fluorescent antibody stain capable of binding directly or indirectly to the epitope to form non-associated labeled virus-sized particles; and After mixing, fluorescent antibody stain not bound to non-associated labeled particles is not removed from the fluid sample prior to flow cytometry.

21. A method according to any one of claims 1 to 9, wherein the non-associated labeled particles have a maximum cross-sectional dimension in the range of 10 nanometers to 2 micrometers.

22. The method according to any one of claims 1 to 8, wherein the fluorescent antibody stain comprises fluorophores attached to antibody molecules, each antibody molecule comprising an average of 3 to 8 attached fluorophores.

23. The method according to any one of claims 1 to 9, wherein the virus-sized particles are exosomes.

24. The method according to any one of claims 1 to 9, wherein the virus-sized particles are virus-like particles.

25. The method according to any one of claims 1 to 9, wherein the virus-sized particles are virosomes.

26. The method according to any one of claims 1 to 9, wherein the virus type is a baculovirus.

27. The method according to any one of claims 1 to 9, wherein the virus type is Norovirus.

28. The method according to any one of claims 1 to 9, wherein the virus type is an enterovirus.

29. The method according to any one of claims 1 to 9, wherein the virus type is influenza virus.

30. The method according to any one of claims 1 to 9, wherein the virus-sized particle is modified to express a recombinant protein.